CytoDyn (CYDY) 10-Q 11 Apr 22 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Feb. 28, 2022	Mar. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Feb. 28, 2022
Entity File Number	000-49908
Entity Registrant Name	CYTODYN INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-1887078
Entity Address, Address Line One	1111 Main Street
Entity Address, Address Line Two	Suite 660
Entity Address, City or Town	Vancouver
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98660
City Area Code	360
Local Phone Number	980-8524
Title of 12(b) Security	None.
No Trading Symbol Flag	true
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		718,319,606
Current Fiscal Year End Date	--05-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001175680
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Feb. 28, 2022	May 31, 2021
Current assets:
Cash	$ 1,363	$ 33,943
Restricted cash	1,000
Inventories, net	82,668	93,479
Prepaid expenses	6,135	616
Prepaid service fees	1,183	1,543
Total current assets	92,349	129,581
Operating leases - right-of-use asset	570	712
Property and equipment, net	117	134
Intangibles, net	1,043	1,653
Total assets	94,079	132,080
Current liabilities:
Accounts payable	62,393	65,897
Accrued liabilities and compensation	9,418	19,073
Accrued interest on convertible notes	4,857	2,007
Accrued dividends on convertible preferred stock	3,635	2,647
Operating leases	136	175
Convertible notes payable, net	35,647	62,747
Total current liabilities	116,086	152,546
Long-term liabilities:
Long-term liabilities - operating leases	453	552
Total liabilities	116,539	153,098
Commitments and Contingencies (Note 10)
Stockholders' (deficit) equity:
Preferred stock
Common stock, $0.001 par value; 1,000,000 shares authorized; 713,730 and 626,123 issued, and 713,287 and 625,680 outstanding at February 28, 2022 and May 31, 2021, respectively	713	626
Additional paid-in capital	612,905	512,796
Accumulated deficit	(636,078)	(534,440)
Treasury stock, $0.001 par value; 443 at February 28, 2022 and May 31, 2021
Total stockholders' deficit	(22,460)	(21,018)
Total liabilities and stockholders' equity	94,079	132,080
Series B Convertible Preferred Stock
Stockholders' (deficit) equity:
Preferred stock
Series C Convertible Preferred Stock
Current liabilities:
Accrued dividends on convertible preferred stock	1,886	1,530
Stockholders' (deficit) equity:
Preferred stock
Series D Convertible Preferred Stock
Current liabilities:
Accrued dividends on convertible preferred stock	1,749	1,117
Stockholders' (deficit) equity:
Preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Feb. 28, 2022	May 31, 2021
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000	5,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000	1,000,000
Common stock, shares issued	713,730	626,123
Common stock, shares outstanding	713,287	625,680
Treasury stock, shares	443	443
Treasury Stock
Common stock, par value	$ 0.001	$ 0.001
Series B Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	400	400
Preferred stock, shares issued	19	79
Preferred stock, shares outstanding	19	79
Series C Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	8	8
Preferred stock, shares issued	7	8
Preferred stock, shares outstanding	7	8
Series D Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	12	12
Preferred stock, shares issued	9	9
Preferred stock, shares outstanding	9	9

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Income Statement [Abstract]
Product revenue			$ 266	$ 0
Total revenues			266
Cost of goods sold			53
Total cost of goods sold			53
Gross margin			213
Operating expenses:
General and administrative	$ 10,140	$ 7,902	33,960	25,328
Research and development	9,128	12,323	31,952	44,061
Amortization and depreciation	129	511	657	1,522
Intangible asset impairment charge		10,049		10,049
Total operating expenses	19,397	30,785	66,569	80,960
Operating loss	(19,397)	(30,785)	(66,356)	(80,960)
Interest and other expense:
Interest on convertible notes	(1,187)	(1,257)	(4,299)	(2,870)
Amortization of discount on convertible notes	(637)	(157)	(2,382)	(2,739)
Amortization of debt issuance costs	(19)	(21)	(70)	(40)
Loss on extinguishment of convertible notes	(3,109)	(7,625)	(11,072)	(11,794)
Finance charges	(7,025)	(1)	(8,084)	(138)
Inducement interest expense	(954)	(5,360)	(6,186)	(12,922)
Legal settlement			(1,941)
Total interest and other expense	(12,931)	(14,421)	(34,034)	(30,503)
Loss before income taxes	(32,328)	(45,206)	(100,390)	(111,463)
Income tax benefit	0	0	0	0
Net loss	$ (32,328)	$ (45,206)	$ (100,390)	$ (111,463)
Earnings Per Share, Basic	$ (0.05)	$ (0.08)	$ (0.15)	$ (0.19)
Earnings Per Share, Diluted	$ (0.05)	$ (0.08)	$ (0.15)	$ (0.18)
Weighted Average Number of Shares Outstanding, Basic	695,614	577,854	663,373	595,226
Weighted Average Number of Shares Outstanding, Diluted	695,614	577,854	663,373	595,226

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' (Deficit) Equity - USD ($) shares in Thousands, $ in Thousands	Preferred Stock	Common StockPrivate Warrant Exchange [Member]	Common StockPrivate Equity Offering	Common Stock	Treasury Stock	Additional Paid-in CapitalPrivate Warrant Exchange [Member]	Additional Paid-in CapitalPrivate Equity Offering	Additional Paid-in Capital	Accumulated Deficit	Private Warrant Exchange [Member]	Private Equity Offering	Total
Beginning balance at May. 31, 2020				$ 519				$ 372,301	$ (375,301)			$ (2,481)
Beginning balance, shares at May. 31, 2020	109			519,261	286
Issuance of stock for convertible note repayment, value				$ 2				9,535				9,537
Issuance of stock for convertible note, shares				2,119
Issuance of legal settlement, warrants, value				$ 4				(4)
Issuance of legal settlement, warrants, shares				4,000
Exercise of stock option, value								(39)				(39)
Exercise of stock option, shares				100
Stock issued via offering, tender or placement, value		$ 17				$ 7,787				$ 7,804
Stock issued via offering, tender or placement, shares		16,544
Conversion of preferred stock to common stock, shares	(5)			50
Warrant exercises, value				$ 28				12,662				12,690
Warrant exercises, shares				27,928
Inducement interest expense related to private warrant exchange						3,345				3,345
Dividend declared and paid									(243)			(243)
Dividends accrued on preferred stock									(420)			(420)
Stock-based compensation								2,865				2,865
Offering costs, stock and warrants						(364)				(364)
Stock issued for incentive compensation and tendered for income tax								828				828
Stock issued for incentive compensation and tendered for income tax , shares				323	156
Net loss									(30,832)			(30,832)
Ending balance at Aug. 31, 2020				$ 570				408,994	(406,796)			2,768
Ending balance, shares at Aug. 31, 2020	104			570,325	442
Beginning balance at May. 31, 2020				$ 519				372,301	(375,301)			(2,481)
Beginning balance, shares at May. 31, 2020	109			519,261	286
Net loss												(111,463)
Ending balance at Feb. 28, 2021				$ 609				471,849	(488,253)			(15,795)
Ending balance, shares at Feb. 28, 2021	96			609,420	442
Beginning balance at May. 31, 2020				$ 519				372,301	(375,301)			(2,481)
Beginning balance, shares at May. 31, 2020	109			519,261	286
Ending balance at May. 31, 2021				$ 626				512,796	(534,440)			(21,018)
Ending balance, shares at May. 31, 2021	96			626,123	443
Beginning balance at Aug. 31, 2020				$ 570				408,994	(406,796)			2,768
Beginning balance, shares at Aug. 31, 2020	104			570,325	442
Issuance of stock for convertible note repayment, value				$ 4				11,549				11,553
Issuance of stock for convertible note, shares				4,293
Exercise of stock option, value								10				10
Exercise of stock option, shares				10
Stock issued via offering, tender or placement, value		$ 13	$ 1			4,583	$ 999			4,596	$ 1,000
Stock issued via offering, tender or placement, shares		12,480	667
Warrant exercises, value				$ 2				1,737				1,739
Warrant exercises, shares				2,504
Inducement interest expense related to private warrant exchange						4,217				4,217
Dividends accrued on preferred stock									(415)			(415)
Stock-based compensation								3,423				3,423
Net loss									(35,425)			(35,425)
Ending balance at Nov. 30, 2020				$ 590				435,512	(442,636)			(6,534)
Ending balance, shares at Nov. 30, 2020	104			590,279	442
Issuance of stock for convertible note repayment, value				$ 4				20,500				20,504
Issuance of stock for convertible note, shares				4,013
Exercise of stock option, value				$ 2				1,778				1,780
Exercise of stock option, shares				2,471
Stock issued via offering, tender or placement, value		$ 6				3,461				3,467
Stock issued via offering, tender or placement, shares		5,939
Conversion of preferred stock to common stock, shares	(8)			80
Warrant exercises, value				$ 7				3,432				3,439
Warrant exercises, shares				6,638
Inducement interest expense related to private warrant exchange						5,360				5,360
Dividends accrued on preferred stock									(411)			(411)
Stock-based compensation								1,937				1,937
Offering costs, stock and warrants						(131)				(131)
Net loss									(45,206)			(45,206)
Ending balance at Feb. 28, 2021				$ 609				471,849	(488,253)			$ (15,795)
Ending balance, shares at Feb. 28, 2021	96			609,420	442
Issuance of common stock upon vesting of stock based compensation awards, shares												400
Ending balance at May. 31, 2021				$ 626				512,796	(534,440)			$ (21,018)
Ending balance, shares at May. 31, 2021	96			626,123	443
Issuance of stock for convertible note repayment, value				$ 12				18,483				18,495
Issuance of stock for convertible note, shares				11,816
Issuance of legal settlement, warrants, value								1,744				1,744
Exercise of stock option, value								189				189
Exercise of stock option, shares				300
Stock issued via offering, tender or placement, value		$ 1	$ 3			774	2,869			775	$ 2,872
Stock issued via offering, tender or placement, shares		1,327	2,872
Warrant exercises, value				$ 1				502				503
Warrant exercises, shares				668
Inducement interest expense related to private warrant exchange						528				528
Dividends accrued on preferred stock									(420)			(420)
Stock-based compensation								2,597				2,597
Stock issued for incentive compensation and tendered for income tax				$ 1				(1)
Stock issued for incentive compensation and tendered for income tax , shares				1,014
Net loss									(31,458)			(31,458)
Ending balance at Aug. 31, 2021				$ 644				540,481	(566,318)			(25,193)
Ending balance, shares at Aug. 31, 2021	96			644,120	443
Beginning balance at May. 31, 2021				$ 626				512,796	(534,440)			(21,018)
Beginning balance, shares at May. 31, 2021	96			626,123	443
Stock issued via offering, tender or placement, value										5,400
Conversion of preferred stock to common stock												2
Warrant exercises, shares											23,500
Net loss												(100,390)
Ending balance at Feb. 28, 2022				$ 713				612,905	(636,078)			(22,460)
Ending balance, shares at Feb. 28, 2022	35			713,730	443
Beginning balance at Aug. 31, 2021				$ 644				540,481	(566,318)			(25,193)
Beginning balance, shares at Aug. 31, 2021	96			644,120	443
Issuance of stock for convertible note repayment, value				$ 8				11,505				11,513
Issuance of stock for convertible note, shares				8,162
Exercise of stock option, value								200				200
Exercise of stock option, shares				210
Stock issued via offering, tender or placement, value		$ 7	$ 25			4,608	27,282			4,615	$ 27,307
Stock issued via offering, tender or placement, shares		6,593	25,178
Conversion of preferred stock to common stock				$ 1								1
Conversion of preferred stock to common stock, shares	(60)			600
Warrant exercises, value				$ 1				532				533
Warrant exercises, shares				963
Inducement interest expense related to private warrant exchange						$ 4,704				$ 4,704
Dividend declared and paid								17	(17)
Dividend declared and paid, shares				35
Dividends accrued on preferred stock									(414)			(414)
Stock-based compensation								2,060				2,060
Offering costs, stock and warrants							(1,418)				(1,418)
Net loss									(36,604)			(36,604)
Ending balance at Nov. 30, 2021				$ 686				589,971	(603,353)			(12,696)
Ending balance, shares at Nov. 30, 2021	36			685,861	443
Issuance of stock for convertible note repayment, value				$ 17				12,048				12,065
Issuance of stock for convertible note, shares				17,132
Stock issued via offering, tender or placement, value			$ 7				$ 3,545				$ 3,552
Stock issued via offering, tender or placement, shares			6,860							7,900
Conversion of preferred stock to common stock				$ 2				(2)
Conversion of preferred stock to common stock, shares	(1)			2,200
Warrant exercises, shares				11
Modification of previously issued equity, value				$ 1				953				954
Modification of previously issued equity, shares				1,179
Dividend declared and paid								243				243
Dividend declared and paid, shares				487
Dividends accrued on preferred stock									(397)			(397)
Finance charges related to warrant issuance for surety bond backstop agreement								6,585				6,585
Stock-based compensation								(438)				(438)
Net loss									(32,328)			(32,328)
Ending balance at Feb. 28, 2022				$ 713				$ 612,905	$ (636,078)			$ (22,460)
Ending balance, shares at Feb. 28, 2022	35			713,730	443

Consolidated Statement of Cha_2

Consolidated Statement of Changes in Stockholders' (Deficit) Equity (Parenthetical) - $ / shares	3 Months Ended
	Feb. 28, 2022	Nov. 30, 2021	Aug. 31, 2020
Dividends declared and paid, per share	$ 0.50	$ 0.25	$ 0.25
Private Equity Offering | Maximum
Stock price, in dollars per share	1	1.80
Private Equity Offering | Minimum
Stock price, in dollars per share	$ 0.40	$ 1

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Cash flows from operating activities:
Net loss	$ (32,328)	$ (45,206)	$ (100,390)	$ (111,463)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	129	511	657	1,522
Amortization of debt issuance costs	19	21	70	40
Amortization of discount on convertible notes	637	157	2,382	2,739
Non-cash warrant issuance cost for legal settlement			1,744
Inducement interest expense and non-cash finance charges			14,270	12,922
Inventory reserve and write offs			8,916	4,835
Stock-based compensation			4,219	9,053
Loss on extinguishment of convertible notes	3,109	7,625	11,072	11,794
Intangible asset impairment charge		10,049		10,049
Changes in operating assets and liabilities:
Decrease (increase) in inventories			1,895	(79,226)
(Increase) decrease in prepaid expenses			(5,159)	362
(Decrease) increase in accounts payable and accrued expenses			(11,355)	52,606
Net cash used in operating activities			(71,679)	(84,767)
Cash flows from investing activities:
Furniture and equipment purchases			(30)	(100)
Net cash used in investing activities			(30)	(100)
Cash flows from financing activities:
Proceeds from warrant transactions, net of offering costs			5,390	15,371
Proceeds from sale of common stock and warrants, net of issuance costs			33,313	1,000
Proceeds from warrant exercises			1,036	18,647
Payment on convertible notes				(950)
Release of restricted cash held in trust for warrant tender offer				(10)
Proceeds from stock option exercises			390	1,829
Payment of payroll withholdings related to tender of common stock for income tax withholding				(778)
Proceeds from convertible notes payable, net				50,000
Dividend declared and paid on Series B preferred stock				(243)
Net cash provided by financing activities			40,129	84,866
Net change in cash and restricted cash			(31,580)	(1)
Cash and restricted cash, beginning of period			33,943	14,292
Cash and restricted cash, end of period	2,363	14,291	2,363	14,291
Cash and restricted cash consisted of the following:
Cash	1,363	14,291	1,363	14,291
Restricted cash	1,000		1,000
Total cash and restricted cash	$ 2,363	$ 14,291	2,363	14,291
Supplemental disclosure of cash flow information:
Cash paid during the period for interest			63	140
Non-cash investing and financing transactions:
Issuance of common stock for principal and interest of convertible notes			31,001	29,800
Accrued dividends on convertible Series C and D preferred stock			988	$ 1,246
Dividend declared and paid in common stock on Series B and C preferred stock conversions			260
Common stock issued upon conversion of preferred stock			2
Common stock issued related to modification of equity agreements			$ 1

Organization

Organization	9 Months Ended
	Feb. 28, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Note 1. Organization CytoDyn Inc. (together with its wholly own subsidiaries, the “Company”) was originally incorporated under the laws of Colorado on May 2, 2002, under the name RexRay Corporation and, effective August 27, 2015, reincorporated under the laws of Delaware. The Company is a late-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate,leronlimab (PRO 140), a novel humanized monoclonal antibody targeting the CCR5 receptor. The Company is studying leronlimab in human immunodeficiency virus (“HIV”), oncology, non-alcoholic steatohepatitis (“NASH”), and coronavirus disease (“COVID-19”). The consolidated financial statements include the accounts of CytoDyn Inc. and its wholly owned subsidiaries, CytoDyn Operations Inc. and Advanced Genetic Technologies, Inc. (“AGTI”); AGTI is a dormant entity. Leronlimab is being investigated as a viral entry inhibitor for HIV, believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as NASH. Leronlimab is being studied in NASH, oncology, COVID-19, and other therapeutic indications where CCR5 is believed to play an integral role. ​ The Company capitalizes inventories procured or produced in preparation for product launches sufficient to support estimated initial market demand subject to regulatory approval for commercial sale. The Company believes that material uncertainties related to the ultimate regulatory approval of leronlimab for commercial sale have been significantly reduced based on positive data from its Phase 2b/3 clinical trial for leronlimab as a combination therapy with highly active antiretroviral therapy (“HAART”) for highly treatment-experienced HIV patients, as well as information gathered from meetings with the U.S. Food and Drug Administration (“FDA”) related to its Biologic License Application (“BLA”) for this indication. In July 2020, the Company received a Refusal to File letter from the FDA regarding its BLA submission for leronlimab as a combination therapy with HAART for highly treatment-experienced HIV patients. The FDA informed the Company the BLA did not contain certain information and data needed to complete a substantive review and therefore, the FDA would not file the BLA. The deficiencies cited by FDA included administrative deficiencies, omissions, corrections to data presentation and related analyses, and clarifications regarding the manufacturing processes. The Company is working with consultants to cure the BLA deficiencies noted and plans to resubmit the BLA as soon as practical. In November 2021, the Company resubmitted the non-clinical and chemistry, manufacturing, and controls (“CMC”) sections of the BLA and is currently reevaluating when it expects to complete the clinical section. As of March 2022, the FDA had commenced its review of the CMC section. The Company is in dispute with its former contract research organization (“CRO”), as described in Note 10, Commitments and Contingencies, Legal Proceedings. Summary of Significant Accounting Policies, Inventories Inventories, net, Commitments and Contingencies, Regulatory Matters, . Risk Factors

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Feb. 28, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation The unaudited interim consolidated financial statements include the accounts of CytoDyn Inc. and its subsidiaries and reflect all normal recurring adjustments which are, in the opinion of management, necessary for a fair statement of the results of operations for the interim period. The interim financial information and notes thereto should be read in conjunction with the Company's latest Annual Report on Form 10-K for the fiscal year ended May 31, 2021 The results of operations for the three and nine months ended February 28, 2022, are not necessarily indicative of results to be expected for the entire fiscal year. Reclassifications Certain prior year and prior quarter amounts shown in the accompanying consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications did not have any effect on the Company’s financial position, results of operations, stockholders’ (deficit) equity, or net cash flows previously reported. Correction of Immaterial Misstatements in Prior Period Financial Statements During the preparation of the quarterly financial statements as of and for the period ended November 30, 2021, the Company identified an error in how non-cash inducement interest expense was calculated in previous reporting periods dating back to fiscal year 2018. The original inducement expense model was designed to calculate non-cash inducement interest expense specific to inducements that modified the warrant term (e.g., extension of the term or modification of exercise price) without settling the instrument. However, starting in fiscal year 2018, inducements were primarily structured to result in a settlement of the warrant, not merely a modification of a warrant that would remain outstanding for some period. The error was identified when the model started to calculate a gain on substantially all inducements, which was inconsistent with the economics of the arrangements. The error resulted in an understatement of non-cash inducement interest expense and additional paid-in capital. The Company assessed the materiality of the misstatement in accordance with Accounting Standards Codification (“ASC”) 250, Accounting Changes and Error Corrections Materiality Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements Summary of Significant Accounting Policies, Going Concern The consolidated accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As presented in the accompanying consolidated financial statements, the Company had losses for all periods presented. The Company incurred a net loss of $100.4 million for the nine months ended February 28, 2022 and has an accumulated deficit of $636.1 million as of February 28, 2022. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional operating capital, complete development of its product candidate, leronlimab, obtain approval to commercialize leronlimab from regulatory agencies, continue to outsource manufacturing of leronlimab, and ultimately achieve substantial revenues, and to attain profitability. The Company continues to pursue significant research and development activities related to leronlimab for multiple indications and expects to incur significant research and development expenses in the future primarily related to its clinical trials. These research and development activities are subject to significant risks and uncertainties. The Company intends to finance its future development activities and its working capital needs primarily from the sale of equity and debt securities, combined with additional funding from other traditional sources. However, there can be no assurance, however, that the Company will be successful in these endeavors. ​ Use of Estimates The preparation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates are assessed each period and updated to reflect current information, such as the status of our analysis of the results of our clinical trials and discussions with the United States Food and Drug Administration (the “FDA”) which could have an impact on the Company’s significant accounting estimates and assumptions. The Company’s estimates are based on historical experience and on various market and other relevant, appropriate assumptions. Significant estimates include, but are not limited, to those relating to stock-based compensation, capitalization of pre-launch inventories, reserve for excess and obsolete inventories, revenue recognition, research and development expenses, determination of right of use assets under lease transactions and related lease obligations, commitments and contingencies, and the assumptions used to value warrants, warrant modifications and useful lives for property and equipment and related depreciation calculations. Actual results could differ from these estimates. Revenue Recognition The Company accounts for and recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers Contracts with customers are generally in the form of a written purchase order that outlines the promised goods and the agreed upon price. Such orders are often accompanied by a master supply or distribution agreement that establishes the terms and conditions, rights of the parties, delivery terms, and pricing. The Company assesses collectability based on a number of factors, including the creditworthiness of the customer. For the Company’s sole contract to date, the customer submits purchase orders to purchase of a specified quantity of leronlimab vials; therefore, the delivery of the ordered quantity per the purchase order is accounted for as one performance obligation. The Company does not offer discounts or rebates. The transaction price is determined based on the agreed upon rates per vial indicated in the purchase order or master supply agreement applied to the quantity of leronlimab vials that the customer requested in the purchase order. As the Company’s contracts include only one performance obligation, the delivery of the product to the customer, all of the transaction price is allocated to the one performance obligation. Therefore, upon delivery of the product quantity equal to the quantity requested in the purchase order, there are no remaining performance obligations. The Company’s shipping and handling activities are considered a fulfillment cost. The Company has elected to exclude all sales and value added taxes from the measurement of the transaction price. The Company has not adjusted the transaction price for significant financing since the time period between the transfer of goods and payment is less than one year. The Company recognizes revenue at a point in time when control of the products is transferred to the customer. Management applies judgment in evaluating when a customer obtains control of the promised good which is generally when the product is delivered to the customer. The Company’s customer contract includes a standard assurance warranty to guarantee that its products comply with agreed specifications. The Company grants a conditional right of return of product in the customer’s inventory upon an adverse regulatory ruling. The Company continually evaluates the probability of such occurrence. If necessary, the Company will defer revenue recognized based on its estimate of the right of return, which considers the probability that an adverse regulatory ruling will occur and its estimate of product in the customer’s inventory. Disaggregation of Revenue – Contract Assets and Liabilities – liabilities Performance Obligations – Inventories Previously Expensed Inventories The Company has recorded revenue related to sales of vials for emergency purposes only, solely to treat critically ill COVID-19 patients in the Philippines under Compassionate Special Permit. Cost of goods sold has been minimal because the vials sold were expensed in prior periods as research and development expense, as they were manufactured prior to the Company’s capitalization of pre-launch inventories as described below. Accordingly, all inventory amounts represent pre-launch inventories, and do not include any inventories previously expensed as research and development expense. Capitalized Pre-launch Inventories The Company’s pre-launch inventories consist of raw materials purchased for commercial production and work-in-progress inventory related to the substantially completed commercial production of pre-launch inventories of leronlimab to support the Company’s expected approval of the product as a combination therapy for HIV patients in the United States. Work-in-progress consists of bulk drug substance, which is the manufactured drug stored in bulk storage, and drug product, which is the manufactured drug in unlabeled vials. The Company values inventory at the lower of cost or net realizable value using the average cost method. Inventories consist of raw materials, bulk drug substance, and drug product in unlabeled vials to be used for commercialization of the Company’s biologic, leronlimab, which is in the regulatory approval process. The consumption of raw materials during production is classified as work-in-progress until saleable. Once it is determined to be in saleable condition, following regulatory approval, inventory is classified as finished goods. Inventory is evaluated for recoverability by considering the likelihood that revenue will be obtained from the future sale of the related inventory considering the status of the product within the regulatory approval process. The Company capitalizes inventories procured or produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory begins when the results of clinical trials have reached a status sufficient to support regulatory approval, uncertainties regarding ultimate regulatory approval have been significantly reduced, and the Company has determined it is probable that these capitalized costs will provide future economic benefit in excess of capitalized costs. The material factors considered by the Company in evaluating these uncertainties include the receipt and analysis of positive Phase 3 clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, and status of the Company’s regulatory applications. The Company closely monitors the status of the product within the regulatory review and approval process, including all relevant communications with regulatory authorities. If the Company is aware of any specific material risks or contingencies other than the normal regulatory review and approval process or if there are any specific issues identified relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory may no longer qualify for capitalization. The Company utilizes resins, a reusable raw material, in its bulk drug manufacturing process. Shelf-life of a resin used in commercial manufacturing of biologics is determined by the number of cycles for which it has been validated to be used in a manufacturing process, before it is considered unusable. Unpacked and unused resins have a manufacturer’s expiration date by which resins are expected to start being used in the manufacturing process without loss of their properties. Prior to a new manufacturing campaign, and between manufacturing campaigns, the resins are removed from storage, are treated and tested for suitability. Once resins are used in the manufacturing process, their shelf-life is measured by a validated predetermined number of manufacturing cycles they are usable for, conditional on appropriate storage solution under controlled environment between production campaigns, as well as by performing pre-production usability testing. Before a manufacturing campaign, each resin is tested for suitability. Regardless of the number of cycles, if a resin fails to meet prespecified suitability parameters it may not be used in manufacturing; likewise even if the resin meets suitability criteria beyond the lifetime cycles, it may no longer be used. The cost of the resins used in a manufacturing campaign is allocated to the cost of the drug product in vials. The Company evaluates its inventory levels on a quarterly basis and writes down inventory that became obsolete, has a cost in excess of its expected net realizable value, or is in quantities in excess of expected requirements. In assessing the lower of cost or net realizable value for pre-launch inventory, the Company relies on independent analyses provided by third parties knowledgeable about the range of likely commercial prices comparable to current comparable commercial product. Quarterly, the Company also evaluates whether certain raw materials held in its inventory are expected to reach the end of their estimated shelf-lives based on passage of time, the number of manufacturing cycles they are used in and results of pre-production testing prior to the expected production date, or when resins used in the manufacturing process fail suitability tests, and records reserves if it is expected that such inventories will become obsolete prior to the expected production date. Anticipated future sales, shelf lives, and expected approval date are considered when evaluating realizability of capitalized inventory. The shelf-life of a product is determined as part of the regulatory approval process; however, in assessing whether to capitalize pre-launch inventories, the Company considers the product stability data of all of the pre-approval inventory procured or produced to date to determine whether there is adequate shelf life. When the remaining shelf-life of drug product inventory is less than 12 months, it is likely that it will not be accepted by potential customers. However, as inventories approach their shelf-life expiration, the Company may perform additional stability testing to determine if the inventory is still viable, which can result in an extension of its shelf-life and revaluation of the need for and the amount of the previously recorded reserves. Further, in addition to performing additional stability testing, certain raw materials inventory may be sold in its then current condition prior to reaching expiration. If the Company determines it is not likely shelf-life will be able to be extended or the inventory cannot be sold prior to expiration, the Company will record the inventory down to its net realizable value. Restricted cash The Company records cash received from fundraising activities before the closing of the transaction as restricted cash on its consolidated balance sheets. As of February 28, 2022, the balance was $1.0 million. Refer to Note 12, Subsequent Events For additional information about the Company’s significant accounting policies, refer to Note 2, Summary of Significant Accounting Policies,

Inventories, net

Inventories, net	9 Months Ended
	Feb. 28, 2022
Inventory Disclosure [Abstract]
Inventories, net	Note 3. Inventories, net Inventories, net of reserves, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) February 28, 2022 May 31, 2021 Raw materials ​ $ 19,517 ​ $ 28,085 Work-in-progress ​ 63,151 ​ 65,394 Total inventories, net ​ $ 82,668 ​ $ 93,479 ​ As of February 28, 2022, the remaining shelf-lives of the Company inventories are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands, Expiration period ending February 28,) Remaining shelf-life Raw materials Work-in-progress bulk drug product Work-in-progress finished drug product in vials Total inventories 2022 ​ 0 to 12 months ​ $ 5,828 ​ $ - ​ $ - ​ $ 5,828 2023 ​ 13 to 24 months ​ ​ 16,263 ​ ​ - ​ ​ - ​ ​ 16,263 2024 ​ 25 to 36 months ​ ​ 2,209 ​ ​ - ​ ​ 29,142 ​ ​ 31,351 2025 ​ 37 to 48 months ​ ​ 888 ​ ​ - ​ ​ 32,344 ​ ​ 33,232 2026 ​ 49 to 60 months ​ ​ - ​ ​ - ​ ​ - ​ ​ - Thereafter ​ 61 or more months ​ ​ 157 ​ ​ 1,665 ​ ​ - ​ ​ 1,822 Total inventories ​ ​ ​ ​ 25,345 ​ ​ 1,665 ​ ​ 61,486 ​ ​ 88,496 Inventories reserved ​ ​ ​ ​ (5,828) ​ ​ - ​ ​ - ​ ​ (5,828) Total inventories, net ​ ​ ​ $ 19,517 ​ $ 1,665 ​ $ 61,486 ​ $ 82,668 ​ The Company utilizes resins, a reusable raw material, in its bulk drug manufacturing process. Shelf-life of a resin used in commercial manufacturing of biologics is determined by the number of cycles for which it has been validated to be used in a manufacturing process, before it is considered unusable. Unpacked and unused resins have a manufacturer’s expiration date by which resins are expected to start being used in the manufacturing process without loss of their properties. Prior to a new manufacturing campaign, and between manufacturing campaigns, the resins are removed from storage, are treated and tested for suitability. Once resins are used in the manufacturing process, their shelf-life is measured by a validated predetermined number of manufacturing cycles they are usable for, conditional on appropriate storage solution under controlled environment between production campaigns, as well as by performing pre-production usability testing. Before a manufacturing campaign, each resin is tested for suitability. Regardless of the number of cycles, if a resin fails to meet prespecified suitability parameters it may not be used in manufacturing; likewise even if the resin meets suitability criteria beyond the lifetime cycles, it may no longer be used. The cost of the resins used in a manufacturing campaign is allocated to the cost of the drug product in vials. The Company is in process of validating the resins’ properties based on the number of cycles they have been used for, and the remaining number of manufacturing cycles they may be used for, and expects to conclude its validation by the end of the current fiscal year. At the conclusion of the validation, the Company expects to present shelf-life of resins to be extended beyond the 13 to 24 months, as currently presented and instead to present shelf-life of resins based on remaining production cycles instead of number of months they may be used for. As of February 28, 2022, the Company did not identify any resins that failed suitability validation. During the three and nine months ended February 28, 2022, the Company reserved $3.3 million and $5.1 million, respectively, for estimated obsolescence of raw materials; none during the three and nine months ended February 28, 2021. In addition, during the same periods of fiscal 2022, the Company expensed $1.8 million and $3.8 million, respectively, and $4.8 million during the nine months ended February 28, 2021, of vialed drug product used for clinical purposes and inventory rendered defective due to manufacturing errors committed by the contract manufacturer during the manufacturing process. These expenses are recorded as research and development expenses in the accompanying consolidated statement of operations. The Company believes that material uncertainties related to the ultimate regulatory approval of leronlimab for commercial sale have been significantly reduced based on positive data from its Phase 2b/3 clinical trial for leronlimab as a combination therapy with highly active antiretroviral therapy (“HAART”) for highly treatment-experienced HIV patients, as well as information gathered from meetings with the U.S. Food and Drug Administration (“FDA”) related to its Biologic License Application (“BLA”) for this indication. In July 2020, the Company received a Refusal to File letter from the FDA regarding its BLA submission for leronlimab as a combination therapy with HAART for highly treatment-experienced HIV patients. The FDA informed the Company the BLA did not contain certain information and data needed to complete a substantive review and therefore, the FDA would not file the BLA. The deficiencies cited by FDA included administrative deficiencies, omissions, corrections to data presentation and related analyses, and clarifications regarding the manufacturing processes. The Company is working with consultants to cure the BLA deficiencies noted and plans to resubmit the BLA as soon as practical. In November 2021, the Company resubmitted the non-clinical and CMC sections of the BLA and is currently reevaluating when it expects to complete the clinical section. As of March 2022, the FDA had commenced its review of the CMC section. The Company is in dispute with its former CRO, as described in Note 10, Commitments and Contingencies, Legal Proceedings. Summary of Significant Accounting Policies, Inventories Inventories, net, Commitments and Contingencies, Regulatory Matters, . Risk Factors ​

Intangible assets, net

Intangible assets, net	9 Months Ended
	Feb. 28, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets, net	Note 4. Intangible assets, net Intangible assets were as follows: ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) February 28, 2022 May 31, 2021 Leronlimab (PRO 140) patent ​ $ 3,500 ​ $ 3,500 ProstaGene, LLC intangible asset acquisition, net of impairment ​ 2,926 ​ ​ 2,926 Website development costs ​ 20 ​ 20 Gross carrying value ​ ​ 6,446 ​ ​ 6,446 Accumulated amortization, net of impairment ​ (5,403) ​ (4,793) Total intangible assets, net ​ $ 1,043 ​ $ 1,653 ​ Amortization expense related to intangible assets, all of which are classified as finite-lived, was $0.1 million and $0.7 million, and $0.5 million and $1.5 million for the three and nine months ended February 28, 2022 and 2021, respectively. The Company recognized an impairment charge of $10.0 million related to the ProstaGene, LLC intangible asset acquisition during the quarter ended February 28, 2021. Refer to Note 8, Acquisition of Patents and Intangibles The following table summarizes the estimated aggregate future amortization expense related to the Company’s intangible assets with finite lives as of February 28, 2022: ​ ​ ​ ​ Fiscal Year (in thousands) Amount 2022 (3 months remaining) ​ $ 110 2023 ​ ​ 217 2024 ​ ​ 85 2025 ​ ​ 85 Thereafter ​ ​ 546 Total ​ $ 1,043 ​

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	9 Months Ended
	Feb. 28, 2022
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	Note 5. Accounts Payable and Accrued Liabilities As of February 28, 2022 and May 31, 2021, the accounts payable balance was $62.4 million and $65.9 million, respectively, with two vendors accounting for 62% and 19% and 72% and 14%, respectively, of the total balance of accounts payable and accrued liabilities. The components of accrued liabilities are as follows: ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ February 28, 2022 May 31, 2021 Compensation and related expense ​ $ 1,637 ​ $ 4,005 Legal settlement and fees ​ ​ 3,259 ​ ​ 11,008 Other liabilities ​ 4,522 ​ 4,060 Total accrued liabilities ​ $ 9,418 ​ $ 19,073 ​ As of February 28, 2022, the entire amount of Accrued legal settlement and fees Accrued legal settlement and fees

Convertible Instruments and Acc

Convertible Instruments and Accrued Interest	9 Months Ended
	Feb. 28, 2022
Debt Disclosure [Abstract]
Convertible Instruments and Accrued Interest	Note 6. Convertible Instruments and Accrued Interest Refer to Note 5, Convertible Instruments, Convertible Preferred Stock ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 ​ May 31, 2021 (in thousands) Series B* Series C** Series D** Series B* Series C** Series D** Undeclared dividends ​ $ 8 ​ $ - ​ $ - ​ $ 18 ​ $ - ​ $ - Accrued dividends ​ $ - ​ $ 1,886 ​ $ 1,749 ​ $ - ​ $ 1,530 ​ $ 1,117 Shares of common stock ​ ​ 17 ​ ​ 3,772 ​ ​ 3,498 ​ ​ 36 ​ ​ 3,060 ​ ​ 2,234 * Series B preferred stock allows for non-accumulating dividend rights. ** Series C and D preferred stock allow for accumulating dividend rights. ​ The Company may elect to pay dividends in the Company’s common stock. Shares of common stock presented in the table above represent the number of shares that would have been issued had the dividend been paid in shares of the Company’s common stock as of February 28, 2022 and May 31, 2021. Convertible Notes and Accrued Interest For additional information about the Company’s debt policies, refer to Note 2, Summary of Significant Accounting Policies, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 ​ May 31, 2021 (in thousands) April 2, 2021 Note April 23, 2021 Note Total November 2020 Note April 2, 2021 Note April 23, 2021 Note Total Convertible notes payable outstanding principal ​ $ 9,819 ​ $ 28,500 ​ $ 38,319 ​ $ 13,500 ​ $ 28,500 ​ $ 28,500 ​ $ 70,500 Less: Unamortized debt discount and issuance costs ​ ​ (662) ​ ​ (2,010) ​ ​ (2,672) ​ ​ (1,204) ​ ​ (3,232) ​ ​ (3,317) ​ ​ (7,753) Convertible notes payable, net ​ ​ 9,157 ​ ​ 26,490 ​ ​ 35,647 ​ ​ 12,296 ​ ​ 25,268 ​ ​ 25,183 ​ ​ 62,747 Accrued interest on convertible notes ​ ​ 2,285 ​ ​ 2,572 ​ ​ 4,857 ​ ​ 1,258 ​ ​ 447 ​ ​ 302 ​ ​ 2,007 Outstanding convertible notes payable, net and accrued interest ​ $ 11,442 ​ $ 29,062 ​ $ 40,504 ​ $ 13,554 ​ $ 25,715 ​ $ 25,485 ​ $ 64,754 ​ Changes to the outstanding balance of convertible notes, including accrued interest, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ November 2020 Note ​ April 2, 2021 Note ​ April 23, 2021 Note ​ Total Outstanding balance at May 31, 2021 ​ $ 13,554 ​ $ 25,715 ​ $ 25,485 ​ $ 64,754 Amortization of issuance discount and costs ​ ​ 98 ​ ​ 1,045 ​ ​ 1,309 ​ ​ 2,452 Interest expense ​ ​ 192 ​ ​ 1,839 ​ ​ 2,268 ​ ​ 4,299 Fair market value of shares exchanged for repayment ​ ​ (18,495) ​ ​ (23,578) ​ ​ - ​ ​ (42,073) Debt extinguishment loss ​ ​ 4,651 ​ ​ 6,421 ​ ​ - ​ ​ 11,072 Outstanding balance at February 28, 2022 ​ $ - ​ $ 11,442 ​ $ 29,062 ​ $ 40,504 ​ Long-term Convertible Note - November 2020 Note On November 10, 2020, the Company entered into a securities purchase agreement pursuant to which the Company issued a secured convertible promissory note with a two-year term to an institutional accredited investor in the initial principal amount of $28.5 million (the “November 2020 Note”). The Company received consideration of $25.0 million, reflecting an original issue discount of $3.4 million and issuance costs of $0.1 million. Interest accrued at an annual rate of 10% on the outstanding balance, with the outstanding balance convertible into shares of common stock at an initial conversion price of $10.00 per share upon five In addition, the Company was obligated to make monthly payments to reduce the outstanding balance of the note. Convertible Instruments On June 11, 2021, June 21, 2021, and June 30, 2021, in partial satisfaction of the June 2021 debt redemption amount on the November 2020 Note, the Company and the investor entered into separately negotiated exchange agreements, pursuant to which the November 2020 Note was partitioned into new notes (the “June 2021 Partitioned Notes”) with a principal balance of $6.0 million. The Company and the holder of the November 2020 Note agreed to defer the remaining $1.5 million of the June 2021 debt redemption amount. The outstanding balance of the November 2020 Note was reduced by the June 2021 Partitioned Notes, and the Company and the investor exchanged the June 2021 Partitioned Notes for approximately 4.2 million shares of the Company’s common stock. On July 14, 2021 and July 27, 2021, in partial satisfaction of the July 2021 debt reduction amount, the Company and the November 2020 Note holder entered into exchange agreements, pursuant to which the November 2020 Note was partitioned into new notes (the “July 2021 Partitioned Notes”) with a principal amount of $4.0 million. The Company and the holder of the November 2020 Note agreed to defer the remaining $3.5 million of the July 2021 debt redemption amount. The outstanding balance of the November 2020 Note was reduced by the July 2021 Partitioned Notes. The Company and the investor exchanged the July 2021 Partitioned Notes for approximately 3.3 million shares of common stock. On August 4, 2021, August 16, 2021, and August 30, 2021, in partial satisfaction of the August 2021 debt reduction amount, the Company and the November 2020 Note holder entered into exchange agreements, pursuant to which the remaining principal and accrued balance of the November 2020 Note was partitioned into new notes (the “August 2021 Partitioned Notes”) with a principal amount of $4.9 million. The Company and the holder of the November 2020 Note agreed to defer the remaining $2.6 million of the August 2021 debt reduction amount. The Company and the investor exchanged the August 2021 Partitioned Notes for approximately 4.4 million shares of common stock. Following the redemption, the obligation under the November 2020 Note was fully satisfied. Amortization of debt discounts and issuance costs, and interest expense during nine months ended February 28, 2022 were $0.1 million and $0.2 million, respectively; none in three months ended February 28, 2022 for either of the expenses In connection with the June 2021 Partitioned Notes, July 2021 Partitioned Notes, and August 2021 Partitioned Notes, the Company analyzed the restructured notes for potential requirement of debt extinguishment accounting under ASC 470-50-40-10, Debt Modifications and Extinguishments Long-term Convertible Note - April 2, 2021 Note On April 2, 2021, the Company entered into a securities purchase agreement pursuant to which the Company issued a secured convertible promissory note with a two-year term with the holder of the November 2020 Note in the initial principal amount of $28.5 million (the “April 2, 2021 Note”). The Company received consideration of $25.0 million, reflecting an original issue discount of $3.4 million and issuance costs of $0.1 million. Interest accrues at an annual rate of 10% on the outstanding balance, with the rate increasing to the lesser of 22% per annum or the maximum rate permitted by applicable law upon occurrence of an event of default. In addition, upon any event of default, the investor may accelerate the outstanding balance payable under the April 2, 2021 Note; upon such acceleration, the outstanding balance will increase automatically by 15%, 10% or 5%, depending on the nature of the event of default. The events of default are listed in Section 4 of the April 2, 2021 Note filed as Exhibit 4.1 Pursuant to the terms of the securities purchase agreement and the April 2, 2021 Note, the Company must obtain the investor’s consent before assuming additional debt with aggregate net proceeds to the Company of less than $50.0 million. In the event of any such approval, the outstanding principal balance of the April 2, 2021 Note will increase automatically by 5% upon the issuance of such additional debt . The investor may convert all or any part the outstanding balance of the April 2, 2021 note into shares of common stock at an initial conversion price of $10.00 per share upon five three Company to satisfy its redemption obligations in cash within three In addition, beginning in May 2021 and for each of the following five months, the Company was obligated through end of November 2021, at discretion of the noteholder, to reduce the outstanding balance of the April 2, 2021 Note by $7.5 million per month. Payments under the November 2020 Note and the April 23, 2021 Note, described below, could be applied toward the payment of each monthly debt reduction amount. These payments are not subject to the 15% prepayment premium, which would otherwise be triggered if the Company were to make payments against such notes exceeding the allowed maximum monthly redemption amount. The Company filed a Registration Statement on Form S-3 (Registration No. 333-258944) with the SEC on August 19, 2021, which was declared effective on October 6, 2021, registering a number of shares of common stock sufficient to convert the entire principal balance of the April 2, 2021 Note and the April 23, 2021 Note (described below). The conversion feature of the April 2, 2021 Note was analyzed under ASC 815, Derivatives and Hedging In September 2021, the Company and the holder of the April 2, 2021 Note agreed to defer the $7.5 million September 2021 debt redemption amount. On October 5, 2021 and October 21, 2021, in partial satisfaction of the October 2021 debt reduction amount, the Company and the April 2, 2021 Note holder entered into exchange agreements, pursuant to which the April 2, 2021 Note was partitioned into new notes (the “October 2021 Partitioned Notes”) with a principal amount of $5.0 million. The Company and the holder of the April 2, 2021 Note agreed to defer the remaining October 2021 debt redemption amount of $2.5 million. The outstanding balance of the April 2, 2021 Note was reduced by the October 2021 Partitioned Notes. The Company and the investor exchanged the October 2021 Partitioned Notes for approximately 3.9 million shares of common stock. On November 2, 2021 and November 16, 2021, in partial satisfaction of the outstanding principal amount, the Company and the April 2, 2021 note holder entered into exchange agreements, pursuant to which the April 2, 2021 Note was partitioned into new notes (the “November 2021 Partitioned Notes”) with a principal amount of $4.0 million. The Company and the investor exchanged the November 2021 Partitioned Notes for approximately 4.2 million shares of common stock. On December 7, 2021 and December 29, 2021, in partial satisfaction of the outstanding principal amount, the Company and the April 2, 2021 note holder entered into exchange agreements, pursuant to which the April 2, 2021 Note was partitioned into new notes (the “December 2021 Partitioned Notes”) with a principal amount of $4.0 million. The Company and the investor exchanged the December 2021 Partitioned Notes for approximately 4.8 million shares of common stock. On January 19, 2022, in partial satisfaction of the outstanding principal amount, the Company and the April 2, 2021 Note holder entered into an exchange agreement, pursuant to which the April 2, 2021 Note was partitioned into a new note (the “January 2022 Partitioned Note”) with a principal amount of $2.5 million. The Company and the investor exchanged the January 2022 Partitioned Note for approximately 5.4 million shares of common stock. On February 18, 2022, in partial satisfaction of the outstanding principal amount, the Company and the April 2, 2021 Note holder entered into an exchange agreement, pursuant to which the April 2, 2021 Note was partitioned into a new note (the “February 2022 Partitioned Note”) with a principal amount of $3.2 million. The Company and the investor exchanged the February 2022 Partitioned Note for approximately 7.0 million shares of common stock. Amortization of debt discounts and issuance costs associated with the April 2, 2021 Note during the three and nine months ended February 28, 2022 was $0.2 million and $1.0 million, respectively. As of February 28, 2022, the unamortized discount and issuance costs balance was $0.7 million; the accrued interest balance was $2.3 million, which included $1.8 million of interest expense for the nine months ended February 28, 2022. In connection with the October 2021 to February 2022 Partitioned Notes, the Company analyzed the restructured notes against debt extinguishment accounting under ASC 470-50-40-10, Debt Modifications and Extinguishments Long-term Convertible Note - April 23, 2021 Note On April 23, 2021, the Company entered into a securities purchase agreement pursuant to which the Company issued a secured convertible promissory note with a two-year term to an institutional accredited investor affiliated with the holder of the November 2020 and April 2, 2021 Notes in the initial principal amount of $28.5 million (the “April 23, 2021 Note”). The Company received consideration of $25.0 million, reflecting an original issue discount of $3.4 million and issuance costs of $0.1 million. The April 23, 2021 Note is secured by all the assets of the Company, excluding the Company’s intellectual property. Interest accrues at an annual rate of 10% on the outstanding balance of the April 23, 2021 Note, with the rate increasing to the lesser of 22% per annum or the maximum rate permitted by applicable law upon the occurrence of an event of default. In addition, upon any event of default, the investor may accelerate the outstanding balance payable under the April 23, 2021 Note; upon such acceleration, the outstanding balance will increase automatically by 15%, 10% or 5%, depending on the nature of the event of default. The events of default are listed in Section 4 of the April 23, 2021 Note filed as Exhibit 4.1 The investor may convert all or any part of the outstanding balance into shares of common stock at an initial conversion price of $10.00 per share upon five The investor may redeem any portion of the April 23, 2021 Note, at any time beginning six months after the issue date, upon three three Pursuant to the terms of the securities purchase agreement and the April 23, 2021 Note, the Company must obtain the investor’s consent before assuming additional debt with aggregate net proceeds to the Company of less than $75.0 million. In the event of any such approval, the outstanding principal balance of the April 23, 2021 Note will increase automatically by 5% upon the issuance of such additional debt. Amortization of debt discounts and issuance costs associated with the April 23, 2021 Note during the three and nine months ended February 28, 2022 was $0.4 million and $1.3 million, respectively. As of February 28, 2022, the unamortized discount and issuance costs balance was $2.0 million; the accrued interest balance was $2.6 million, which included $2.3 million of interest expense for the nine months ended February 28, 2022. The conversion feature in the April 23, 2021 Note was analyzed under ASC 815, Derivatives and Hedging ​ The holders of the April 2 and April 23 Notes have waived provisions in the notes that would have resulted in the imposition of a default interest rate, a downward adjustment in the conversion price, or any other default, breach or imposition of a penalty. The related transactions consisted of the issuance of warrants to purchase 30 million shares of common stock with registration rights to the Indemnitors pursuant to a Backstop Agreement, and the grant of a security interest in the Company’s intellectual property to Indemnitors that are parties to the Backstop Agreement. The noteholders also waived similar rights relating to the issuances of approximately 13 million shares of common stock and shares underlying warrants to investors between February and March 2022, in private placements conducted by the Company. Refer to Note 7, Equity Awards and Warrants

Equity Awards and Warrants

Equity Awards and Warrants	9 Months Ended
	Feb. 28, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Awards and Warrants	Note 7. Equity Awards and Warrants Stock option and warrants activity is presented in the table below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ Weighted ​ remaining ​ Aggregate ​ ​ Number of ​ average ​ contractual ​ intrinsic (in thousands, except per share data) shares exercise price life in years value Options and warrants outstanding at May 31, 2021 61,573 ​ $ 0.95 4.40 ​ $ 68,756 Granted 40,557 ​ $ 0.81 — ​ — Exercised (5,677) ​ $ 0.71 — ​ — Forfeited or expired and cancelled (13,395) ​ $ 1.26 — ​ — Options and warrants outstanding February 28, 2022 83,058 ​ $ 0.85 4.40 ​ $ 4,653 Options and warrants outstanding and exercisable at February 28, 2022 75,770 ​ $ 0.76 3.91 ​ $ 4,651 ​ As of February 28, 2022, approximately 11.3 million outstanding stock options were vested, approximately 7.4 million outstanding stock options were unvested, and all outstanding warrants were exercisable. In the three and nine months ended February 28, 2022 and 2021, stock-based compensation expense related to equity instruments discussed herein totaled $(0.4) million and $4.2 million, and $1.9 million and $9.1 million, respectively, presented in general and administrative expense in the Company’s consolidated statements of operations. Stock-based compensation expense recognized in general and administrative expense for three and nine months ended February 28, 2022 included approximately $1.3 million of forfeitures of unvested equity awards related to the termination of the Company’s former CEO see Former CEO Severance in Common Stock Private Placement of Warrants under Surety Bond Backstop Agreement ​ Equity Incentive Plan As of February 28, 2022, the Company had one active stock-based equity plan, the CytoDyn Inc. Amended and Restated 2012 Equity Incentive Plan Stock Options and Other Equity Awards During the nine months ended February 28, 2022, the Company granted stock options covering a total of approximately 11.2 million shares of common stock to employees with exercise prices ranging from $0.58 to $2.23 per share. The stock options generally vest over three years, have a ten-year term, and a grant date fair value between $0.45 and $1.71 per share. During the nine months ended February 28, 2022, the Company issued approximately 0.5 million shares of common stock in connection with the exercise of stock options. The stated exercise price was between $0.63 and $1.06 per share, which resulted in aggregate gross proceeds of $0.4 million to the Company. During the nine months ended February 28, 2022, the Company issued approximately 0.4 million shares of common stock in connection with the vesting of performance stock units (“PSUs”) awarded in June 2020. The PSUs were subject to the Compensation Committee’s determination of the level of achievement of certain performance conditions set forth in the respective award agreements. The original awards covered a total of 4.35 million PSUs, of which approximately 3.9 million PSUs were forfeited. In connection with the approximate 0.4 million vested shares, the Company recognized $1.3 million in stock-based compensation expense in the fourth quarter of fiscal year 2021. During the nine months ended February 28, 2022, the Company issued approximately 0.4 million shares of common stock in connection with the time-based vesting of restricted stock units (“RSUs”) for which it recognized $0.4 million in stock-based compensation expense. Also, during the nine months ended February 28, 2022, certain members of management received shares of fully vested common stock in lieu of a portion of their cash bonus for services in fiscal year 2021 totaling approximately 0.2 million shares of common stock. The Company recognized $0.3 million of expense for these shares in lieu of cash bonus during the fourth quarter of fiscal year 2021. Private Placement of Shares of Common Stock and Warrants During the nine months ended February 28, 2022, the Company entered into privately negotiated warrant exchange agreements with certain accredited investors, pursuant to which the investors purchased shares of common stock at exercise prices ranging from $0.40 to $1.00 per share. The Company issued approximately 3.5 million shares of common stock under the original warrants, as well as additional shares as an inducement to equity holders to exercise their warrants, for a total of approximately 7.9 million shares of common stock. In connection with these transactions, the Company recognized $5.2 million of inducement interest expense in the nine months ended February 28, 2022 (none in the three months ended February 2022). The total proceeds were $5.4 million. During the nine months ended February 28, 2022, 23.5 c share one s a p a During the three months ended February 28, 2022, in connection with the private placement to accredited investors described above, certain accredited investors who participated in previous private placements purchased 6.3 million shares of common stock, together with warrants with exercise prices ranging from $0.40 to $1.00 per share, to purchase a total of approximately 2.8 million shares of common stock. In connection with these purchases, the Company modified agreements related to issuances in the previous private placement, effectively lowering the purchase price of common shares, lowering the exercise price of the underlying warrants, and increasing the warrant coverage on the common stock purchased, resulting in the issuance of an additional 1.2 million shares of common stock and 0.6 million warrants with exercise prices of $0.45 to $1.00. As the result of these modifications, the Company recorded inducement interest expense of approximately $1.0 million for the three months ended February 28, 2022. During the nine months ended February 28, 2022, the Company settled a dispute with a placement agent in part by the issuance of warrants covering 1.6 million shares of common stock that expire in seven years and have a stated exercise price of $0.40 per share. The expense is presented as legal settlement expense in the accompanying consolidated statement of operations and consists of a $0.2 million cash payment and $1.7 million of non-cash expense related to the issuance of warrants. On February 16, 2022, the Company issued to a third-party consultant as consideration for services a warrant to purchase 25,000 shares of common stock at an exercise price of $1.04 per share and with a term expiring on December 6, 2031. The warrant is fully vested as to 15,000 shares with the remainder vesting on December 6, 2022, subject to forfeiture if the consultant ceases to provide services to the Company prior to that date. The Company recognized $14 thousand in stock-based compensation related to this award in the three months ended February 28, 2022. Private Placement of Warrants under Surety Bond Backstop Agreement On February 14, 2022, the Company entered into a Surety Bond Backstop Agreement (the “Backstop Agreement”) with an accredited investor in his individual capacity and as trustee of a revocable trust as well as certain other related parties (collectively, the “Indemnitors”). Pursuant to the Backstop Agreement, the Indemnitors agreed to assist the Company in obtaining a surety bond (the “Surety Bond”) for posting in connection with the Company’s ongoing litigation with Amarex Clinical Research, LLC ("Amarex”), by, among other things, agreeing to indemnify the issuer of the Surety Bond with respect to the Company’s obligations under the Surety Bond. Under the Backstop Agreement, as consideration for the Company’s indemnity of the Surety Bond, the Company agreed to issue a warrant for the purchase of 15.0 million shares of common stock as a backstop fee (the “Initial Warrant”), and to issue an additional warrant for the purchase of 15.0 million shares of common stock, with the additional warrant to be exercised only if the Indemnitors are required to make any payment to the issuer of the Surety Bond as a result of their indemnification (the “Make-Whole Warrant”). If the Indemnitors are required to make any such payment within 90 days of the payment by the Indemnitors, the Company has agreed to reimburse the Indemnitors for any amount paid by them to the issuer of the Surety Bond and to pay to the Indemnitors an indemnification fee in an amount equal to 1.5 times the amount paid by the Indemnitors to the issuer of the Surety Bond. The Initial Warrant has a five-year term. The Make-Whole Warrant is exercisable, if at all, beginning on the date that payment by the Indemnitors to the issuer of the Surety Bond is required (the “Commencement Date”) and ending on the later of (i) five years following the date of issuance of the Make- Whole Warrant and (ii) five years following the Commencement Date if such date occurs within two years following issuance of both warrants. The exercise price of the warrants is $0.30 per share. The payment obligations of the Company to the Indemnitors under the Backstop Agreement bear interest at 10% per annum and are secured by a security interest granted by the Company to the Indemnitors on substantially all of the patents of the Company. For further description of the Backstop Agreement, refer to the Company’s Current Report on Form 8-K filed with the SEC on February 17, 2022. The Company recognized approximately a $6.6 million finance charge related to the warrant issuance for the three months ended February 28, 2022. Private Placement of Common Stock and Warrants through Placement Agent During the nine months ended February 28, 2022, the Company issued in a private placement to accredited investors an aggregate of approximately 11.4 million shares of common stock, together with warrants to purchase an aggregate of approximately 5.0 million shares of common stock at an exercise price of $1.00 per share. The securities were issued at a combined purchase price of $1.00 per fixed combination of one share of common stock and three -tenths of one warrant to purchase one share of common stock, for aggregate gross and net proceeds to the Company of $11.4 million and $10.0 million, respectively. The warrants have a five-year term and are immediately exercisable. A copy of the form of warrant was filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 7, 2021 . The Company paid a cash fee to the placement agent in an amount equal to 12% of the gross proceeds received from qualified investors in the offering, as well as a one-time non-accountable expense fee of $50,000 . The Company also issued warrants with an exercise price of $1.00 per share and a 10-year term to purchase shares in an amount equal to 12% of the total shares of common stock sold to qualified investors in the offering. In satisfaction of the fees, the Company issued warrants for shares of common stock. Former CEO Severance in Common Stock On January 24, 2022, the Board of Directors terminated the employment of the Company’s President and Chief Executive Officer, Nader Z. Pourhassan, Ph.D. (the “former CEO”), and removed him as an officer of the Company. Under the terms of his employment agreement, Dr. Pourhassan was also deemed to resign, without any further action or notice, from all positions held with the Company and its subsidiaries, including, without limitation, as a member of the Board. Under the terms of the severance agreement and in accordance with the employment agreement, as amended, with the former CEO, the Company is obligated to pay severance within 60 days of separation, as a lump sum, in the amount of 12 months of salary in effect at the time of separation, and another six months of salary paid in monthly installments beginning 180 days after the termination date. The employment agreement permits the severance payments to be made in whole or in part through the issuance of shares of common stock. As of February 28, 2022, the amount of severance was recorded in Accrued liabilities and compensation in the consolidated balance sheet. Effective March 8, 2022, Dr. Pourhassan and the Company entered into a separation and release of claims agreement with terms consistent with his employment agreement. On March 25, 2022, the Company issued 908,418 shares of common stock in satisfaction of the lump sum amount.

Loss Per Common Share

Loss Per Common Share	9 Months Ended
	Feb. 28, 2022
Earnings Per Share [Abstract]
Loss Per Common Share	Note 8. Loss per Common Share Basic loss per share is computed by dividing the net loss adjusted for preferred stock dividends by the weighted average number of common shares outstanding during the period. Diluted loss per share includes the weighted average common shares outstanding and potentially dilutive common stock equivalents. Because of the net losses for all periods presented, the basic and diluted weighted average shares outstanding are the same since including the additional shares would have an anti-dilutive effect on the loss per share. The table below shows the number of shares of common stock issuable upon the exercise, vesting or conversion of outstanding options, warrants, unvested restricted stock units (including those subject to performance conditions), convertible notes, and convertible preferred stock (including undeclared dividends) that were not included in the computation of basic and diluted weighted average number of shares of common stock outstanding for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three and nine months ended February 28, ​ (in thousands) 2022 2021 ​ Stock options, warrants, and unvested restricted stock units ​ 98,309 ​ 68,857 ​ Convertible notes ​ 12,000 ​ 12,000 ​ Convertible preferred stock ​ 32,197 ​ 32,159 ​ ​ ​

Income Taxes

Income Taxes	9 Months Ended
	Feb. 28, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes The Company calculates its quarterly taxes under the effective tax rate method based on applying an anticipated annual effective rate to its year-to-date income, except for discrete items. Income taxes for discrete items are computed and recorded in the period that the specific transaction occurs. ​ The Company’s net tax expense for the three and nine months ended February 28, 2022 and February 28, 2021, was zero. The Company’s effective tax rate of 0% differed from the statutory rate of 21% because the Company has a full valuation allowance as of February 28, 2022 and May 31, 2021, because management does not consider it more likely than not that the benefits from the net deferred taxes will be realized.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Feb. 28, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10. Commitments and Contingencies Refer to Note 10, Commitments and Contingencies Commitments with Samsung BioLogics Co., Ltd. (“Samsung”) In April 2019, the Company entered into an agreement with Samsung, pursuant to which Samsung will perform technology transfer, process validation, manufacturing, and supply services for the commercial supply of leronlimab effective through calendar year 2027. In 2020, the Company entered into an additional agreement, pursuant to which Samsung will perform technology transfer, process validation, vial filling and storage services for clinical, pre-approval inspection, and commercial supply of leronlimab. Samsung is obligated to procure necessary raw materials for the Company and manufacture a specified minimum number of batches, and the Company is required to provide a rolling three-year forecast of future estimated manufacturing requirements to Samsung that are binding. On January 6, 2022, Samsung provided written notice to the Company alleging that the Company had materially breached the parties’ Master Services and Project Specific Agreements for failure to pay $13.5 million due on December 31, 2021. An additional $22.8 million became due under the agreements on January 31, 2022, and was included in accounts payable as of February 28, 2022. The Company has notified Samsung that it believes a material breach will not be deemed to have occurred under the terms of the agreements until July 1, 2022. Under the agreements, the Company has 45 days to make commercially reasonable efforts to commence curing a material breach and, if such steps have not been taken during the cure period, Samsung is entitled to terminate the agreements upon an additional 45 days’ notice. Management is in ongoing discussions with Samsung regarding potential approaches to resolve these issues, including proposals by both parties of a revised schedule of payments over an extended period of time, and proposals by the Company of satisfaction of a portion of the Company’s payment obligations in equity securities of the Company and postponing or cancelling the manufacturing of additional drug product provided for in the agreements. As of February 28, 2022, the Company had past due balances of approximately $38.1 million due to Samsung which were included in accounts payable as of February 28, 2022. As of February 28, 2022, the future commitments pursuant to these agreements were estimated as follows: ​ ​ ​ ​ ​ Fiscal Year (in thousands) Amount 2022 (3 months remaining) ​ $ 2,418 2023 ​ ​ 32,221 2024 ​ ​ 121,750 2025 ​ ​ 76,400 Total ​ $ 232,789 ​ Commitments with Contract Research Organization (“CRO”) The Company continues to maintain agreements with its CRO and related laboratory vendors to perform project work for each of the clinical trials. Under the terms of these agreements, the Company prepaid execution fees for direct services costs, which are recorded as a current asset. In the event the Company were to terminate any trial, it may incur certain financial penalties that would become payable to the CRO. Conditioned upon the form of termination of any one trial, the financial penalties may range up to $0.2 million. In the remote circumstance that the Company would terminate all clinical trials, the collective financial penalties may range from a low of approximately $20.0 thousand to an approximate high of $0.6 million. Distribution and Licensing Refer to Note 9, License Agreements The Company has two license agreements, the fees for which are payable annually in December, with a third-party licensor covering the licensor’s “system know-how” technology with respect to the Company’s use of proprietary cell lines to manufacture new leronlimab material. As of February 28, 2022, the Company accrued $0.4 million related to the arrangements. As of May 31, 2021 the Company recorded a prepaid asset of $0.1 million related to this agreement. In December 2019, the Company entered into Commercialization and License Agreement, and Supply Agreement (together the “License Agreements”) with Vyera Pharmaceuticals, LLC (“Vyera”) under which the Company granted Vyera an exclusive royalty-bearing license to commercialize pharmaceutical preparations containing leronlimab for treatment of HIV in the United States. The License Agreements gave Vyera the right to assign its rights and obligations under the Licence Agreements to an affiliate of Vyera. In October 2020, Vyera assigned the License Agreements to SevenScore Pharmaceuticals, which in turn, in December 2021, assigned them to Regnum Corp. Vyera, SevenScore and Regnum are each controlled by their parent Phoenixus AG. The License Agreements, as assigned, provide that, pursuant to the terms and subject to the conditions set forth therein, Regnum will, at its cost, use commercially reasonable efforts to commercialize leronlimab for treatment of HIV in the United States. The Company retained the right to license leronlimab for uses in the United States for purposes other than the treatment of HIV and for any purposes outside the United States. The License Agreements obligate Regnum to pay the Company up to $87.0 million upon the achievement of certain sales and regulatory milestones. Certain milestones are subject to reduction if not achieved within an agreed-upon timeframe. Regnum may also pay the Company additional potential milestone payments upon the regulatory approval of leronlimab for certain subsequent indications in the field. Whether a particular subsequent indication qualifies for an additional milestone payment will be determined in good faith by the parties at the time such an event occurs. In addition, during the Royalty Term, as defined in the License Agreements, but, in any event, a period of not less than 10 years following the first commercial sale under the License Agreements, Regnum is obligated to pay the Company a royalty equal to 50% of Regnum’s gross profit margin from product sales. The royalty is subject to reduction during the Royalty Term after patent expiry and expiry of regulatory exclusivity. Following expiration of the Royalty Term, Regnum has non-exclusive rights to commercialize the product. Regnum has the right to terminate the License Agreements (i) upon written notice to the Company on or after December 19, 2021 and prior to the Company’s receipt of approval from the FDA of the BLA for the manufacture and sale of leronlimab for HIV, (ii) if Regnum fails to achieve certain aggregate Net Sales (as defined in the License Agreements) of leronlimab during the period beginning on the date of first commercial sale and ending on the date that is two years from the date of the first commercial sale, and (iii) with 180 days’ prior written notice, at Regnum’s convenience following the second anniversary of the first commercial sale of leronlimab. On April 6, 2021, the Company entered into an exclusive supply and distribution agreement with Biomm S.A., a Brazilian pharmaceutical company, granting the exclusive right to distribute and sell leronlimab in Brazil upon Brazilian regulatory approval. On April 15, 2021, the Company entered into an exclusive supply and distribution agreement with Chiral Pharma Corporation, a Philippine pharmaceutical company, granting the exclusive right to distribute and sell up to 200,000 vials of leronlimab during the 12 months ending April 15, 2022, to treat critically ill COVID-19 patients in the Philippines under CSP or Emergency Use Authorization (“EUA”) from the Food and Drug Administration of the Philippines. On May 11, 2021, the Company entered into an exclusive supply and distribution agreement with Macleods Pharmaceuticals Ltd., an Indian pharmaceutical company, granting the exclusive right to distribute and sell up to 200,000 vials of leronlimab in calendar year 2021 in India to treat COVID-19 patients under a CSP or EUA from the India Central Drugs Standard Control Organization. As further described in Item I, Business Legal Proceedings The Company is a party to various legal proceedings. The Company recognizes accruals for such proceedings to the extent a loss is determined to be both probable and reasonably estimable. The best estimate of a loss within a possible range is accrued; however, if no estimate in the range is more probable than another, then the minimum amount in the range is accrued. If it is determined that a material loss is not probable but reasonably possible and the loss or range of loss can be estimated, the possible loss is disclosed. It is not possible to determine the outcome of proceedings that have not been concluded, including the defense and other litigation-related costs and expenses that may be incurred by the Company, as the outcomes of legal proceedings are inherently uncertain, and the outcomes could differ significantly from recognized accruals. Therefore, it is possible that the ultimate outcome of any proceeding, if in excess of a recognized accrual or if an accrual had not been made, could be material to the Company’s consolidated financial statements. Refer to Note 10, Commitments and Contingencies, Legal Proceedings Shareholder Derivative Lawsuit under Section 16(b) of the Securities Exchange Act On September 10, 2020, certain stockholders of the Company filed a derivative action in the U.S. District Court for the Western District of Washington against then CEO Nader Z. Pourhassan, Ph.D. The plaintiffs claimed that certain of Dr. Pourhassan’s transactions in the Company’s common stock violated Section 16(b) of the Securities Exchange Act of 1934. The Company was only a nominal defendant in the action, and the plaintiffs sought no relief against the Company. On March 12, 2021, the district court granted Dr. Pourhassan’s motion to dismiss the plaintiffs’ complaint with prejudice. The plaintiffs timely appealed that decision to the U.S. Court of Appeals for the Ninth Circuit. On April 8, 2022, the Court of Appeals affirmed the district court’s ruling. Pestell Employment Dispute On August 22, 2019, Dr. Richard Pestell filed a lawsuit in the U.S. District Court for the District of Delaware ( Pestell v. CytoDyn Inc., et al ProstaGene LLC (of which Dr. Pestell was a controlling owner) which are currently held in escrow; and approximately $31.3 million in additional damages as described above. The Company disputes all of Dr. Pestell’s claims and intends to vigorously defend the action and assert its counterclaims. The Company cannot predict the ultimate outcome of the action and cannot reasonably estimate the potential loss or range of loss, if any, that the Company may incur. ​ Securities Class Action Lawsuit On March 17, 2021, a stockholder filed a putative class-action lawsuit (the “March 17, 2021 lawsuit”) in the U.S. District Court for the Western District of Washington against the Company and certain current and former officers. The complaint generally alleges the defendants made false and misleading statements regarding the viability of leronlimab as a potential treatment for COVID-19. On April 9, 2021, a second stockholder filed a similar putative class action lawsuit in the same court, which the plaintiff voluntarily dismissed without prejudice on July 23, 2021. On August 9, 2021, the court appointed lead plaintiffs for the March 17, 2021 lawsuit. On December 21, 2021, lead plaintiffs filed an amended complaint, which is brought on behalf of an alleged class of those who purchased the Company’s common stock between March 27, 2020 and May 17, 2021. The amended complaint generally alleges that the Company and certain current and former officers violated Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making purportedly false or misleading statements concerning, among other things, the safety and efficacy of leronlimab as a potential treatment for COVID-19, the Company’s CD10 and CD12 clinical trials, and its HIV BLA. The amended complaint also alleges that the individual defendants violated Section 20A of the Exchange Act by selling shares of the Company’s common stock purportedly while in possession of material nonpublic information. The amended complaint seeks, among other relief, a ruling that the case may proceed as a class action and unspecified damages and attorneys’ fees and costs. On February 25, 2022, the defendants filed a motion to dismiss the amended complaint. The Company and the individual defendants deny all allegations of wrongdoing in the complaint and intend to vigorously defend the matter. Since this case is in an early stage where the number of plaintiffs is not known, and the claims do not specify an amount of damages, the Company is unable to predict the ultimate outcome of the lawsuit and cannot reasonably estimate the potential loss or range of loss the Company may incur. 2021 Shareholder Derivative Lawsuits On June 4, 2021, a stockholder filed a purported derivative lawsuit against certain of the Company’s current and former officers, certain current and former Board members, and the Company as a nominal defendant, in the U.S. District Court for the Western District of Washington. Two additional shareholder derivative lawsuits were filed against the same defendants in the same court on June 25, 2021 and August 18, 2021, respectively. The court has consolidated these three lawsuits for all purposes (“Consolidated Derivative Suit”). On January 20, 2022, the plaintiffs filed a consolidated complaint. The consolidated complaint generally alleges that the director defendants breached their fiduciary duties by allowing the Company to make false and misleading statements regarding, among other things, the safety and efficacy of leronlimab as a potential treatment for COVID-19, the Company’s CD10 and CD12 clinical trials, and its HIV BLA, and by failing to maintain an adequate system of oversight and controls. The consolidated complaint also asserts claims against one or more individual defendants for waste of corporate assets, unjust enrichment, contribution for alleged violations of the federal securities laws, and for breach of fiduciary duty arising from alleged insider trading. The consolidated complaint seeks declaratory and equitable relief, an unspecified amount of damages, and attorneys’ fees and costs. The Company and the individual defendants deny all allegations of wrongdoing in the complaints and intend to vigorously defend the litigation. In light of the fact that the Consolidated Derivative Suit is in an early stage and the claims do not specify an amount of damages, the Company cannot predict the ultimate outcome of the Consolidated Derivative Suit and cannot reasonably estimate the potential loss or range of loss the Company may incur. Securities and Exchange Commission and Department of Justice Investigations The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security. The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any. Amarex Dispute On October 4, 2021, the Company filed a complaint for declaratory and injunctive relief and a motion for a preliminary injunction against NSF International, Inc. and its subsidiary Amarex Clinical Research LLC (“Amarex”), the Company’s former CRO. Over the past eight years, Amarex provided clinical trial management services to the Company and managed numerous clinical studies of the Company’s drug product candidate, leronlimab. On December 16, 2021, the U.S. District Court for the District of Maryland issued a preliminary injunction requiring Amarex to provide the Company with access to all of its materials in the possession of Amarex. The court also granted CytoDyn the right to conduct an audit of Amarex’s work for CytoDyn. The Company simultaneously filed a demand for arbitration with the American Arbitration Association. The arbitration demand alleges that Amarex failed to perform services to an acceptable professional standard and failed to perform certain services required by the parties’ agreements. Further, the demand alleges that Amarex billed the Company for services it did not perform. The Company contends that, due to Amarex’s failures, it has suffered avoidable delays in obtaining regulatory approval of leronlimab and has paid for services not performed. In light of the fact that this dispute is in an early stage, the Company cannot predict the ultimate outcome of the lawsuit and cannot reasonably estimate the potential loss or range of loss that the Company may incur.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Feb. 28, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions The Board’s Audit Committee, composed of independent directors, or the full Board, reviews and approves all related party transactions. The terms and amounts described below are not necessarily indicative of the terms and amounts that would have been incurred had comparable transactions been entered into with independent parties. On September 23, 2021, Jordan G. Naydenov, a member of the Board, entered into a private warrant exchange in which he exercised warrants to purchase approximately 0.6 million shares of common stock, as well as approximately 0.6 million additional shares that were offered as an inducement to exercise his warrants, for a total of approximately 1.3 million shares of common stock. The terms and conditions of the investment totaling $0.7 million made by Mr. Naydenov were identical to those offered to other investors.

Subsequent Events

Subsequent Events	9 Months Ended
	Feb. 28, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events On March 18, 2022, the Company issued to an accredited investor in a private placement a total of 2,500,000 shares of common stock, together with warrants to purchase a total of 1,250,000 shares of common stock at an exercise price of $0.40 per share. The warrants have a five-year term and are immediately exercisable. The securities were issued with a combined purchase price of $0.40 per fixed combination of one share of common stock and one million. On March 25, 2022, the Board of Directors approved the continued appointment of the individuals currently on the Company’s Scientific Advisory Board (the “SAB”) and appointed four new individuals to the SAB. In consideration for their service, each SAB member is awarded an annual grant of options to purchase 50,000 shares of common stock. The stock options generally vest over three years and have a ten-year term. Effective February 24, 2022, nonqualified stock options were granted to the SAB members exercisable for a total of On March 27, 2022, the Board of Directors approved the appointment of Karen J. Brunke, Ph.D., as a director of the Company, subject to satisfactory completion of a background check. Her appointment was effective on March 30, 2022. The Board also appointed Dr. Brunke to the Board’s Compensation Committee and Audit Committee. On March 31, 2022, the Company announced that the FDA placed a full clinical hold on its COVID-19 program and a partial clinical hold on its HIV program in the United States. The Company previously had notified FDA that it was pausing its COVID-19 trials in Brazil. Under the partial clinical hold on the Company’s HIV program, no clinical studies may be initiated or resumed until the partial clinical hold has been resolved. As a result of the partial clinical hold on the HIV program, patients currently enrolled in the extension trials will be transitioned to other available therapeutics. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. In early April 2022, the Company commenced an offering of up to 61.3 million units, with each unit consisting of one share of common stock and three -quarters of a warrant to purchase one share of common stock. The offering is being conducted in a private placement through a placement agent in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated by the SEC thereunder. The securities being offered will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The intended use of proceeds is to fund operations and for general corporate purposes, including the reduction of indebtedness.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Feb. 28, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim consolidated financial statements include the accounts of CytoDyn Inc. and its subsidiaries and reflect all normal recurring adjustments which are, in the opinion of management, necessary for a fair statement of the results of operations for the interim period. The interim financial information and notes thereto should be read in conjunction with the Company's latest Annual Report on Form 10-K for the fiscal year ended May 31, 2021 The results of operations for the three and nine months ended February 28, 2022, are not necessarily indicative of results to be expected for the entire fiscal year.
Reclassifications	Reclassifications Certain prior year and prior quarter amounts shown in the accompanying consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications did not have any effect on the Company’s financial position, results of operations, stockholders’ (deficit) equity, or net cash flows previously reported.
Correction of Immaterial Misstatements in Prior Period Financial Statements	Correction of Immaterial Misstatements in Prior Period Financial Statements During the preparation of the quarterly financial statements as of and for the period ended November 30, 2021, the Company identified an error in how non-cash inducement interest expense was calculated in previous reporting periods dating back to fiscal year 2018. The original inducement expense model was designed to calculate non-cash inducement interest expense specific to inducements that modified the warrant term (e.g., extension of the term or modification of exercise price) without settling the instrument. However, starting in fiscal year 2018, inducements were primarily structured to result in a settlement of the warrant, not merely a modification of a warrant that would remain outstanding for some period. The error was identified when the model started to calculate a gain on substantially all inducements, which was inconsistent with the economics of the arrangements. The error resulted in an understatement of non-cash inducement interest expense and additional paid-in capital. The Company assessed the materiality of the misstatement in accordance with Accounting Standards Codification (“ASC”) 250, Accounting Changes and Error Corrections Materiality Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements Summary of Significant Accounting Policies,
Going Concern	Going Concern The consolidated accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As presented in the accompanying consolidated financial statements, the Company had losses for all periods presented. The Company incurred a net loss of $100.4 million for the nine months ended February 28, 2022 and has an accumulated deficit of $636.1 million as of February 28, 2022. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional operating capital, complete development of its product candidate, leronlimab, obtain approval to commercialize leronlimab from regulatory agencies, continue to outsource manufacturing of leronlimab, and ultimately achieve substantial revenues, and to attain profitability. The Company continues to pursue significant research and development activities related to leronlimab for multiple indications and expects to incur significant research and development expenses in the future primarily related to its clinical trials. These research and development activities are subject to significant risks and uncertainties. The Company intends to finance its future development activities and its working capital needs primarily from the sale of equity and debt securities, combined with additional funding from other traditional sources. However, there can be no assurance, however, that the Company will be successful in these endeavors. ​
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates are assessed each period and updated to reflect current information, such as the status of our analysis of the results of our clinical trials and discussions with the United States Food and Drug Administration (the “FDA”) which could have an impact on the Company’s significant accounting estimates and assumptions. The Company’s estimates are based on historical experience and on various market and other relevant, appropriate assumptions. Significant estimates include, but are not limited, to those relating to stock-based compensation, capitalization of pre-launch inventories, reserve for excess and obsolete inventories, revenue recognition, research and development expenses, determination of right of use assets under lease transactions and related lease obligations, commitments and contingencies, and the assumptions used to value warrants, warrant modifications and useful lives for property and equipment and related depreciation calculations. Actual results could differ from these estimates.
Revenue Recognition	Revenue Recognition The Company accounts for and recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers Contracts with customers are generally in the form of a written purchase order that outlines the promised goods and the agreed upon price. Such orders are often accompanied by a master supply or distribution agreement that establishes the terms and conditions, rights of the parties, delivery terms, and pricing. The Company assesses collectability based on a number of factors, including the creditworthiness of the customer. For the Company’s sole contract to date, the customer submits purchase orders to purchase of a specified quantity of leronlimab vials; therefore, the delivery of the ordered quantity per the purchase order is accounted for as one performance obligation. The Company does not offer discounts or rebates. The transaction price is determined based on the agreed upon rates per vial indicated in the purchase order or master supply agreement applied to the quantity of leronlimab vials that the customer requested in the purchase order. As the Company’s contracts include only one performance obligation, the delivery of the product to the customer, all of the transaction price is allocated to the one performance obligation. Therefore, upon delivery of the product quantity equal to the quantity requested in the purchase order, there are no remaining performance obligations. The Company’s shipping and handling activities are considered a fulfillment cost. The Company has elected to exclude all sales and value added taxes from the measurement of the transaction price. The Company has not adjusted the transaction price for significant financing since the time period between the transfer of goods and payment is less than one year. The Company recognizes revenue at a point in time when control of the products is transferred to the customer. Management applies judgment in evaluating when a customer obtains control of the promised good which is generally when the product is delivered to the customer. The Company’s customer contract includes a standard assurance warranty to guarantee that its products comply with agreed specifications. The Company grants a conditional right of return of product in the customer’s inventory upon an adverse regulatory ruling. The Company continually evaluates the probability of such occurrence. If necessary, the Company will defer revenue recognized based on its estimate of the right of return, which considers the probability that an adverse regulatory ruling will occur and its estimate of product in the customer’s inventory. Disaggregation of Revenue – Contract Assets and Liabilities – liabilities Performance Obligations –
Inventory	Inventories Previously Expensed Inventories The Company has recorded revenue related to sales of vials for emergency purposes only, solely to treat critically ill COVID-19 patients in the Philippines under Compassionate Special Permit. Cost of goods sold has been minimal because the vials sold were expensed in prior periods as research and development expense, as they were manufactured prior to the Company’s capitalization of pre-launch inventories as described below. Accordingly, all inventory amounts represent pre-launch inventories, and do not include any inventories previously expensed as research and development expense. Capitalized Pre-launch Inventories The Company’s pre-launch inventories consist of raw materials purchased for commercial production and work-in-progress inventory related to the substantially completed commercial production of pre-launch inventories of leronlimab to support the Company’s expected approval of the product as a combination therapy for HIV patients in the United States. Work-in-progress consists of bulk drug substance, which is the manufactured drug stored in bulk storage, and drug product, which is the manufactured drug in unlabeled vials. The Company values inventory at the lower of cost or net realizable value using the average cost method. Inventories consist of raw materials, bulk drug substance, and drug product in unlabeled vials to be used for commercialization of the Company’s biologic, leronlimab, which is in the regulatory approval process. The consumption of raw materials during production is classified as work-in-progress until saleable. Once it is determined to be in saleable condition, following regulatory approval, inventory is classified as finished goods. Inventory is evaluated for recoverability by considering the likelihood that revenue will be obtained from the future sale of the related inventory considering the status of the product within the regulatory approval process. The Company capitalizes inventories procured or produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory begins when the results of clinical trials have reached a status sufficient to support regulatory approval, uncertainties regarding ultimate regulatory approval have been significantly reduced, and the Company has determined it is probable that these capitalized costs will provide future economic benefit in excess of capitalized costs. The material factors considered by the Company in evaluating these uncertainties include the receipt and analysis of positive Phase 3 clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, and status of the Company’s regulatory applications. The Company closely monitors the status of the product within the regulatory review and approval process, including all relevant communications with regulatory authorities. If the Company is aware of any specific material risks or contingencies other than the normal regulatory review and approval process or if there are any specific issues identified relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory may no longer qualify for capitalization. The Company utilizes resins, a reusable raw material, in its bulk drug manufacturing process. Shelf-life of a resin used in commercial manufacturing of biologics is determined by the number of cycles for which it has been validated to be used in a manufacturing process, before it is considered unusable. Unpacked and unused resins have a manufacturer’s expiration date by which resins are expected to start being used in the manufacturing process without loss of their properties. Prior to a new manufacturing campaign, and between manufacturing campaigns, the resins are removed from storage, are treated and tested for suitability. Once resins are used in the manufacturing process, their shelf-life is measured by a validated predetermined number of manufacturing cycles they are usable for, conditional on appropriate storage solution under controlled environment between production campaigns, as well as by performing pre-production usability testing. Before a manufacturing campaign, each resin is tested for suitability. Regardless of the number of cycles, if a resin fails to meet prespecified suitability parameters it may not be used in manufacturing; likewise even if the resin meets suitability criteria beyond the lifetime cycles, it may no longer be used. The cost of the resins used in a manufacturing campaign is allocated to the cost of the drug product in vials. The Company evaluates its inventory levels on a quarterly basis and writes down inventory that became obsolete, has a cost in excess of its expected net realizable value, or is in quantities in excess of expected requirements. In assessing the lower of cost or net realizable value for pre-launch inventory, the Company relies on independent analyses provided by third parties knowledgeable about the range of likely commercial prices comparable to current comparable commercial product. Quarterly, the Company also evaluates whether certain raw materials held in its inventory are expected to reach the end of their estimated shelf-lives based on passage of time, the number of manufacturing cycles they are used in and results of pre-production testing prior to the expected production date, or when resins used in the manufacturing process fail suitability tests, and records reserves if it is expected that such inventories will become obsolete prior to the expected production date. Anticipated future sales, shelf lives, and expected approval date are considered when evaluating realizability of capitalized inventory. The shelf-life of a product is determined as part of the regulatory approval process; however, in assessing whether to capitalize pre-launch inventories, the Company considers the product stability data of all of the pre-approval inventory procured or produced to date to determine whether there is adequate shelf life. When the remaining shelf-life of drug product inventory is less than 12 months, it is likely that it will not be accepted by potential customers. However, as inventories approach their shelf-life expiration, the Company may perform additional stability testing to determine if the inventory is still viable, which can result in an extension of its shelf-life and revaluation of the need for and the amount of the previously recorded reserves. Further, in addition to performing additional stability testing, certain raw materials inventory may be sold in its then current condition prior to reaching expiration. If the Company determines it is not likely shelf-life will be able to be extended or the inventory cannot be sold prior to expiration, the Company will record the inventory down to its net realizable value.
Restricted cash	Restricted cash The Company records cash received from fundraising activities before the closing of the transaction as restricted cash on its consolidated balance sheets. As of February 28, 2022, the balance was $1.0 million. Refer to Note 12, Subsequent Events

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
	Feb. 28, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	​ ​ ​ ​ ​ ​ ​ ​ (in thousands) February 28, 2022 May 31, 2021 Raw materials ​ $ 19,517 ​ $ 28,085 Work-in-progress ​ 63,151 ​ 65,394 Total inventories, net ​ $ 82,668 ​ $ 93,479
Schedule of remaining shelf life of inventory	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands, Expiration period ending February 28,) Remaining shelf-life Raw materials Work-in-progress bulk drug product Work-in-progress finished drug product in vials Total inventories 2022 ​ 0 to 12 months ​ $ 5,828 ​ $ - ​ $ - ​ $ 5,828 2023 ​ 13 to 24 months ​ ​ 16,263 ​ ​ - ​ ​ - ​ ​ 16,263 2024 ​ 25 to 36 months ​ ​ 2,209 ​ ​ - ​ ​ 29,142 ​ ​ 31,351 2025 ​ 37 to 48 months ​ ​ 888 ​ ​ - ​ ​ 32,344 ​ ​ 33,232 2026 ​ 49 to 60 months ​ ​ - ​ ​ - ​ ​ - ​ ​ - Thereafter ​ 61 or more months ​ ​ 157 ​ ​ 1,665 ​ ​ - ​ ​ 1,822 Total inventories ​ ​ ​ ​ 25,345 ​ ​ 1,665 ​ ​ 61,486 ​ ​ 88,496 Inventories reserved ​ ​ ​ ​ (5,828) ​ ​ - ​ ​ - ​ ​ (5,828) Total inventories, net ​ ​ ​ $ 19,517 ​ $ 1,665 ​ $ 61,486 ​ $ 82,668

Intangible assets, net (Tables)

Intangible assets, net (Tables)	9 Months Ended
	Feb. 28, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ (in thousands) February 28, 2022 May 31, 2021 Leronlimab (PRO 140) patent ​ $ 3,500 ​ $ 3,500 ProstaGene, LLC intangible asset acquisition, net of impairment ​ 2,926 ​ ​ 2,926 Website development costs ​ 20 ​ 20 Gross carrying value ​ ​ 6,446 ​ ​ 6,446 Accumulated amortization, net of impairment ​ (5,403) ​ (4,793) Total intangible assets, net ​ $ 1,043 ​ $ 1,653
Schedule of estimated future amortization expense	The following table summarizes the estimated aggregate future amortization expense related to the Company’s intangible assets with finite lives as of February 28, 2022: ​ ​ ​ ​ Fiscal Year (in thousands) Amount 2022 (3 months remaining) ​ $ 110 2023 ​ ​ 217 2024 ​ ​ 85 2025 ​ ​ 85 Thereafter ​ ​ 546 Total ​ $ 1,043

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
	Feb. 28, 2022
Payables and Accruals [Abstract]
Schedule of the components of accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ February 28, 2022 May 31, 2021 Compensation and related expense ​ $ 1,637 ​ $ 4,005 Legal settlement and fees ​ ​ 3,259 ​ ​ 11,008 Other liabilities ​ 4,522 ​ 4,060 Total accrued liabilities ​ $ 9,418 ​ $ 19,073

Convertible Instruments and A_2

Convertible Instruments and Accrued Interest (Tables)	9 Months Ended
	Feb. 28, 2022
Debt Disclosure [Abstract]
Schedule of information on dividends of convertible preferred stock	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 ​ May 31, 2021 (in thousands) Series B* Series C** Series D** Series B* Series C** Series D** Undeclared dividends ​ $ 8 ​ $ - ​ $ - ​ $ 18 ​ $ - ​ $ - Accrued dividends ​ $ - ​ $ 1,886 ​ $ 1,749 ​ $ - ​ $ 1,530 ​ $ 1,117 Shares of common stock ​ ​ 17 ​ ​ 3,772 ​ ​ 3,498 ​ ​ 36 ​ ​ 3,060 ​ ​ 2,234 * Series B preferred stock allows for non-accumulating dividend rights. ** Series C and D preferred stock allow for accumulating dividend rights.
Schedule of outstanding balances of convertible notes	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ February 28, 2022 ​ May 31, 2021 (in thousands) April 2, 2021 Note April 23, 2021 Note Total November 2020 Note April 2, 2021 Note April 23, 2021 Note Total Convertible notes payable outstanding principal ​ $ 9,819 ​ $ 28,500 ​ $ 38,319 ​ $ 13,500 ​ $ 28,500 ​ $ 28,500 ​ $ 70,500 Less: Unamortized debt discount and issuance costs ​ ​ (662) ​ ​ (2,010) ​ ​ (2,672) ​ ​ (1,204) ​ ​ (3,232) ​ ​ (3,317) ​ ​ (7,753) Convertible notes payable, net ​ ​ 9,157 ​ ​ 26,490 ​ ​ 35,647 ​ ​ 12,296 ​ ​ 25,268 ​ ​ 25,183 ​ ​ 62,747 Accrued interest on convertible notes ​ ​ 2,285 ​ ​ 2,572 ​ ​ 4,857 ​ ​ 1,258 ​ ​ 447 ​ ​ 302 ​ ​ 2,007 Outstanding convertible notes payable, net and accrued interest ​ $ 11,442 ​ $ 29,062 ​ $ 40,504 ​ $ 13,554 ​ $ 25,715 ​ $ 25,485 ​ $ 64,754 ​
Schedule of rollforward of the outstanding balance of convertible notes	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ November 2020 Note ​ April 2, 2021 Note ​ April 23, 2021 Note ​ Total Outstanding balance at May 31, 2021 ​ $ 13,554 ​ $ 25,715 ​ $ 25,485 ​ $ 64,754 Amortization of issuance discount and costs ​ ​ 98 ​ ​ 1,045 ​ ​ 1,309 ​ ​ 2,452 Interest expense ​ ​ 192 ​ ​ 1,839 ​ ​ 2,268 ​ ​ 4,299 Fair market value of shares exchanged for repayment ​ ​ (18,495) ​ ​ (23,578) ​ ​ - ​ ​ (42,073) Debt extinguishment loss ​ ​ 4,651 ​ ​ 6,421 ​ ​ - ​ ​ 11,072 Outstanding balance at February 28, 2022 ​ $ - ​ $ 11,442 ​ $ 29,062 ​ $ 40,504 ​

Equity Awards and Warrants (Tab

Equity Awards and Warrants (Tables)	9 Months Ended
	Feb. 28, 2022
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option and Warrant Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ average ​ ​ ​ ​ ​ ​ ​ Weighted ​ remaining ​ Aggregate ​ ​ Number of ​ average ​ contractual ​ intrinsic (in thousands, except per share data) shares exercise price life in years value Options and warrants outstanding at May 31, 2021 61,573 ​ $ 0.95 4.40 ​ $ 68,756 Granted 40,557 ​ $ 0.81 — ​ — Exercised (5,677) ​ $ 0.71 — ​ — Forfeited or expired and cancelled (13,395) ​ $ 1.26 — ​ — Options and warrants outstanding February 28, 2022 83,058 ​ $ 0.85 4.40 ​ $ 4,653 Options and warrants outstanding and exercisable at February 28, 2022 75,770 ​ $ 0.76 3.91 ​ $ 4,651

Loss Per Common Shares (Tables)

Loss Per Common Shares (Tables)	9 Months Ended
	Feb. 28, 2022
Earnings Per Share [Abstract]
Schedule of securities excluded from computation of earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ Three and nine months ended February 28, ​ (in thousands) 2022 2021 ​ Stock options, warrants, and unvested restricted stock units ​ 98,309 ​ 68,857 ​ Convertible notes ​ 12,000 ​ 12,000 ​ Convertible preferred stock ​ 32,197 ​ 32,159 ​

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Feb. 28, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of future commitments	​ ​ ​ ​ ​ Fiscal Year (in thousands) Amount 2022 (3 months remaining) ​ $ 2,418 2023 ​ ​ 32,221 2024 ​ ​ 121,750 2025 ​ ​ 76,400 Total ​ $ 232,789

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Going concern (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Feb. 28, 2022	Nov. 30, 2021	Aug. 31, 2021	Feb. 28, 2021	Nov. 30, 2020	Aug. 31, 2020	Feb. 28, 2022	Feb. 28, 2021	May 31, 2021
Accounting Policies [Abstract]
Net loss	$ 32,328	$ 36,604	$ 31,458	$ 45,206	$ 35,425	$ 30,832	$ 100,390	$ 111,463
Accumulated deficit	$ 636,078						$ 636,078		$ 534,440

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Accounting Policies [Abstract]
Contract with Customer, Asset, after Allowance for Credit Loss	$ 0	$ 0	$ 0	$ 0
Contract with Customer, Liability	0		0
Revenue from Contract with Customer, Excluding Assessed Tax			266	0
Contract with Customer, Liability, Revenue Recognized	$ 0	$ 0	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Restricted cash (Details) $ in Thousands	Feb. 28, 2022USD ($)
Accounting Policies [Abstract]
Restricted cash	$ 1,000

Inventories, net (Details)

Inventories, net (Details) - USD ($) $ in Thousands	Feb. 28, 2022	May 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 19,517	$ 28,085
Work in progress	63,151	65,394
Total inventories, net	$ 82,668	$ 93,479

Inventories, net - Shelf-life (

Inventories, net - Shelf-life (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	May 31, 2021
Inventory Realizable Value [Abstract]
Remaining shelf life 12 or less months	$ 5,828		$ 5,828
Remaining shelf life 12 to 24 months	16,263		16,263
Remaining shelf life 24 to 36 months	31,351		31,351
Remaining shelf life 36 to 48 months	33,232		33,232
Remaining shelf life 60 or more months	1,822		1,822
Total inventories	88,496		88,496
Inventories reserved	(5,828)		(5,828)
Total inventories, net	82,668		82,668		$ 93,479
Inventory Write-down, Obsolescence Of Raw Materials	3,300	$ 0	5,100	$ 0
Inventory Write-down, expired raw materials and untested vialed drug product	1,800		3,800	$ 4,800
Raw Materials [Member]
Inventory Realizable Value [Abstract]
Remaining shelf life 12 or less months	5,828		5,828
Remaining shelf life 12 to 24 months	16,263		16,263
Remaining shelf life 24 to 36 months	2,209		2,209
Remaining shelf life 36 to 48 months	888		888
Remaining shelf life 60 or more months	157		157
Total inventories	25,345		25,345
Inventories reserved	(5,828)		(5,828)
Total inventories, net	19,517		19,517
Bulk Drug Substance [Member]
Inventory Realizable Value [Abstract]
Remaining shelf life 60 or more months	1,665		1,665
Total inventories	1,665		1,665
Total inventories, net	1,665		1,665
Drug Products [Member]
Inventory Realizable Value [Abstract]
Remaining shelf life 24 to 36 months	29,142		29,142
Remaining shelf life 36 to 48 months	32,344		32,344
Total inventories	61,486		61,486
Total inventories, net	$ 61,486		$ 61,486

Intangible Assets, Net - Compon

Intangible Assets, Net - Components (Details) - USD ($) $ in Thousands	Feb. 28, 2022	May 31, 2021
Asset Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross	$ 6,446	$ 6,446
Accumulated amortization, net of impairment	(5,403)	(4,793)
Total amortizable intangible assets, net	1,043	1,653
Website development costs
Asset Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross	20	20
Leronlimab (PRO 140) patent
Asset Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross	3,500	3,500
ProstaGene, LLC acquisition
Asset Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross	$ 2,926	$ 2,926

Intangible Assets, Net - Amorti

Intangible Assets, Net - Amortization Expense Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	May 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 100	$ 500	$ 700	$ 1,500
Intangible asset impairment charge		$ 10,049		$ 10,049
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022 (3 months remaining)	110		110
2023	217		217
2024	85		85
2025	85		85
Thereafter	546		546
Total amortizable intangible assets, net	$ 1,043		$ 1,043		$ 1,653

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) $ in Thousands	9 Months Ended	12 Months Ended
	Feb. 28, 2022USD ($)item	May 31, 2021USD ($)item
Concentration Risk [Line Items]
Accounts payable	$ 62,393	$ 65,897
Number of vendors | item	2	2
Compensation and related expense	$ 1,637	$ 4,005
Legal settlement and fees	3,259	11,008
Other liabilities	4,522	4,060
Total accrued liabilities	$ 9,418	19,073
Accrued legal settlement		$ 10,600
Accounts Payable | Credit Availability Concentration Risk [Member] | Vendor One [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	62.00%	72.00%
Accounts Payable | Credit Availability Concentration Risk [Member] | Vendor Two [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	19.00%	14.00%

Convertible Instruments and A_3

Convertible Instruments and Accrued Interest - Preferred stock (Detail) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Feb. 28, 2022	May 31, 2021
Class of Stock [Line Items]
Accrued dividends	$ 3,635	$ 2,647
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Undeclared dividend	$ 8	$ 18
Shares of common stock	17	36
Series C Convertible Preferred Stock
Class of Stock [Line Items]
Accrued dividends	$ 1,886	$ 1,530
Shares of common stock	3,772	3,060
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Accrued dividends	$ 1,749	$ 1,117
Shares of common stock	3,498	2,234

Convertible Instruments and A_4

Convertible Instruments and Accrued Interest - Outstanding Balance (Details) - USD ($) $ in Thousands	Feb. 28, 2022	May 31, 2021
Debt Instrument [Line Items]
Convertible notes payable outstanding principal	$ 38,319	$ 70,500
Less: Unamortized debt discount and issuance costs	(2,672)	(7,753)
Convertible notes payable, net	35,647	62,747
Accrued interest on convertible notes	4,857	2,007
Outstanding convertible notes payable, net and accrued interest	40,504	64,754
Long-term Convertible Note - November 2020 Note
Debt Instrument [Line Items]
Convertible notes payable outstanding principal		13,500
Less: Unamortized debt discount and issuance costs		(1,204)
Convertible notes payable, net		12,296
Accrued interest on convertible notes		1,258
Outstanding convertible notes payable, net and accrued interest		13,554
Long-term Convertible Note - April 2, 2021 Note
Debt Instrument [Line Items]
Convertible notes payable outstanding principal	9,819	28,500
Less: Unamortized debt discount and issuance costs	(662)	(3,232)
Convertible notes payable, net	9,157	25,268
Accrued interest on convertible notes	2,285	447
Outstanding convertible notes payable, net and accrued interest	11,442	25,715
Long-term Convertible Note - April 23, 2021 Note
Debt Instrument [Line Items]
Convertible notes payable outstanding principal	28,500	28,500
Less: Unamortized debt discount and issuance costs	(2,010)	(3,317)
Convertible notes payable, net	26,490	25,183
Accrued interest on convertible notes	2,572	302
Outstanding convertible notes payable, net and accrued interest	$ 29,062	$ 25,485

Convertible Instruments and A_5

Convertible Instruments and Accrued Interest - Components (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Debt Instrument [Line Items]
Outstanding balance, beginning			$ 64,754
Amortization of issuance discount and costs			2,452
Interest expense			4,299
Cash repayments			(42,073)
Loss on extinguishment of convertible notes	$ 3,109	$ 7,625	11,072	$ 11,794
Outstanding balance, ending	40,504		40,504
Long-term Convertible Note - November 2020 Note
Debt Instrument [Line Items]
Outstanding balance, beginning			13,554
Amortization of issuance discount and costs	0		98
Interest expense			192
Cash repayments			(18,495)
Loss on extinguishment of convertible notes			4,651
Long-term Convertible Note - April 2, 2021 Note
Debt Instrument [Line Items]
Outstanding balance, beginning			25,715
Amortization of issuance discount and costs	200		1,045
Interest expense			1,839
Cash repayments			(23,578)
Loss on extinguishment of convertible notes			6,421
Outstanding balance, ending	11,442		11,442
Long-term Convertible Note - April 23, 2021 Note
Debt Instrument [Line Items]
Outstanding balance, beginning			25,485
Amortization of issuance discount and costs	400		1,309
Interest expense			2,268
Outstanding balance, ending	$ 29,062		$ 29,062

Convertible Instruments and A_6

Convertible Instruments and Accrued Interest - Long-term Convertible Note - November 2020 Note (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Nov. 10, 2020	Aug. 31, 2021	Jul. 31, 2021	Jun. 30, 2021	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	May 31, 2021
Debt Instrument [Line Items]
Net Proceeds								$ 50,000
Amortization of issuance discount and costs							$ 2,452
Accrued interest on convertible notes					$ 4,857		4,857		$ 2,007
Interest on convertible notes					1,187	$ 1,257	4,299	2,870
Long-term Convertible Note - November 2020 Note
Debt Instrument [Line Items]
Debt instrument term	2 years
Convertible note, aggregate principal	$ 28,500
Net Proceeds	25,000
Unamortized discount	3,400
Debt issuance costs	$ 100
Convertible notes, interest rate	10.00%
Conversion price per share	$ 10
Number of days of notice to be given for conversion of notes into common stock	5 days
Loss on extinguishment of convertible notes					0	$ 0	4,700	$ 4,400
Amortization of issuance discount and costs					0		98
Interest on convertible notes					$ 0		$ 200
June 2021 Partitioned Notes
Debt Instrument [Line Items]
Convertible note, aggregate principal				$ 6,000
Shares issued on debt conversion				4.2
Monthly redemption amount deferred				$ 1,500
July 2021 Partitioned Notes
Debt Instrument [Line Items]
Convertible note, aggregate principal			$ 4,000
Shares reserved			3.3
Monthly redemption amount deferred			$ 3,500
August 2021 Partitioned Notes
Debt Instrument [Line Items]
Convertible note, aggregate principal		$ 4,900
Shares reserved		4.4
Monthly redemption amount deferred		$ 2,600

Convertible Instruments and A_7

Convertible Instruments and Accrued Interest - Long-term Convertible Note - April 2, 2021 Note (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Oct. 21, 2021	Oct. 05, 2021	Apr. 02, 2021	Sep. 30, 2021	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	Feb. 18, 2022	Jan. 19, 2022	Dec. 29, 2021	Dec. 07, 2021	Nov. 16, 2021	Nov. 02, 2021	May 31, 2021
Debt Instrument [Line Items]
Net Proceeds								$ 50,000
Amortization of issuance discount and costs							$ 2,452
Accrued interest on convertible notes					$ 4,857		4,857								$ 2,007
Interest on convertible notes					1,187	$ 1,257	4,299	$ 2,870
Net carrying value of note					40,504		40,504								64,754
Long-term Convertible Note - April 2, 2021 Note
Debt Instrument [Line Items]
Debt instrument term			2 years
Convertible note, aggregate principal			$ 28,500
Net Proceeds			25,000
Unamortized discount			3,400
Debt issuance costs			100
Conversion of principal and interest of convertible notes to common stock			$ 3,500
Convertible notes, interest rate			10.00%
Percentage increase in amount payable on default			15.00%
Percentage increase in amount payable, second scenario			10.00%
Percentage increase in amount payable, third default scenario			5.00%
Conversion price per share			$ 10
Number of days of notice to be given for conversion of notes into common stock			5 days
Shares reserved			6
Debt instrument lock in period			6 months
Number of days of notice to be given for redemption			3 days
Specified monthly redemption amount			$ 7,500
Debt instrument prepayment percentage premium			15.00%
Number of days of notice to be given for prepayment			15 days
Period in which company was obligated to reduce the outstanding balance of debt			5 months
Debt proceeds requiring investor consent			$ 50,000
Additional debt, increase in interest rate			5.00%
Amortization of issuance discount and costs					200		1,045
Unamortized discount and issuance costs					700		700
Accrued interest on convertible notes					2,300		2,300
Interest on convertible notes							1,800
Net carrying value of note					11,442		11,442								$ 25,715
Monthly redemption amount deferred				$ 7,500
Loss on extinguishment of convertible notes					$ 3,100		$ 6,400
Long-term Convertible Note - April 2, 2021 Note | Maximum
Debt Instrument [Line Items]
Convertible notes, interest rate			22.00%
October 2021 Partitioned Notes Of April 2021 Notes [Member]
Debt Instrument [Line Items]
Convertible note, aggregate principal	$ 5,000	$ 5,000
Shares reserved	3.9	3.9
Specified monthly redemption amount	$ 2,500	$ 2,500
November 2021 Partitioned Notes Of April 2021 Notes [Member]
Debt Instrument [Line Items]
Convertible note, aggregate principal													$ 4,000	$ 4,000
Shares reserved													4.2	4.2
December 2021 Partitioned Notes Of April 2021 Notes [Member]
Debt Instrument [Line Items]
Convertible note, aggregate principal											$ 4,000	$ 4,000
Shares reserved											4.8	4.8
January 2022 Partitioned Notes Of April 2021 Notes [Member]
Debt Instrument [Line Items]
Convertible note, aggregate principal										$ 2,500
Shares reserved										5.4
February 2022 Partitioned Notes Of April 2021 Notes [Member]
Debt Instrument [Line Items]
Convertible note, aggregate principal									$ 3,200
Shares reserved									7

Convertible Instruments and A_8

Convertible Instruments and Accrued Interest - Long-term Convertible Note - April 23, 2021 Note (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Apr. 23, 2021	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	Mar. 31, 2022	May 31, 2021
Debt Instrument [Line Items]
Net Proceeds					$ 50,000
Amortization of issuance discount and costs				$ 2,452
Accrued interest on convertible notes		$ 4,857		4,857			$ 2,007
Interest on convertible notes		1,187	$ 1,257	4,299	$ 2,870
Net carrying value of note		$ 40,504		$ 40,504			64,754
Indemnitors
Debt Instrument [Line Items]
Warrants to purchase common shares, shares		30		30		13
Private Equity Offering
Debt Instrument [Line Items]
Warrants to purchase common shares, shares		7.3		7.3
Long-term Convertible Note - April 23, 2021 Note
Debt Instrument [Line Items]
Debt instrument term	2 years
Convertible note, aggregate principal	$ 28,500
Net Proceeds	25,000
Unamortized discount	3,400
Debt issuance costs	$ 100
Convertible notes, interest rate	10.00%
Percentage increase in amount payable on default	15.00%
Percentage increase in amount payable, second scenario	10.00%
Percentage increase in amount payable, third default scenario	5.00%
Conversion price per share	$ 10
Number of days of notice to be given for conversion of notes into common stock	5 days
Shares reserved	6
Debt instrument lock in period	6 months
Number of days of notice to be given for redemption	3 days
Threshold trading days to satisfy redemption obligation	3 days
Debt instrument prepayment percentage premium	15.00%
Number of days of notice to be given for prepayment	15 days
Debt proceeds requiring investor consent	$ 75,000
Additional debt, increase in interest rate	5.00%
Amortization of issuance discount and costs		$ 400		$ 1,309
Unamortized discount and issuance costs		2,000		2,000
Accrued interest on convertible notes		2,600		2,600
Interest on convertible notes				2,300
Net carrying value of note		$ 29,062		$ 29,062			$ 25,485
Maximum | Long-term Convertible Note - April 23, 2021 Note
Debt Instrument [Line Items]
Conversion of principal and interest of convertible notes to common stock	$ 7,000
Convertible notes, interest rate	22.00%

Equity Awards and Warrants - Ac

Equity Awards and Warrants - Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Feb. 28, 2022	May 31, 2021
Stock option and warrant activity
Options and warrants outstanding, Number of Shares	61,573
Granted, Number of Shares	40,557
Exercised, Number of Shares	(5,677)
Forfeited/expired/cancelled, Number of Shares	(13,395)
Options and warrants outstanding, Number of Shares	83,058	61,573
Options and warrants outstanding and exercisable, Number of Shares	75,770
Options and warrants outstanding, Weighted Average Exercise Price	$ 0.95
Granted, Weighted Average Exercise Price	0.81
Exercised, Weighted Average Exercise Price	0.71
Forfeited/expired/cancelled, Weighted Average Exercise Price	1.26
Options and warrants outstanding, Weighted Average Exercise Price	0.85	$ 0.95
Options and warrants outstanding and exercisable, Weighted Average Exercise Price	$ 0.76
Options and warrants outstanding, Weighted Average Remaining Contractual Life in Years	4 years 4 months 24 days	4 years 4 months 24 days
Options and warrants outstanding and exercisable, Weighted Average Remaining Contractual Life in Years	3 years 10 months 28 days
Options and warrants outstanding, Aggregate Intrinsic Value	$ 4,653	$ 68,756
Options and warrants outstanding and exercisable, Aggregate Intrinsic Value	$ 4,651
Stock option vested, Shares	11,300,000
Options outstanding, nonvested	7,400,000

Equity Awards and Warrants - Ex

Equity Awards and Warrants - Expense and unrecognized (Details) - USD ($) $ in Thousands, shares in Millions	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense			$ 4,219	$ 9,053
Surety Bond Backstop Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 6,600		$ 6,600
Common stock warrants to purchase shares	15		15
Equity Instruments | General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ (400)	$ 1,900	$ 4,200	$ 9,100
Chief Executive Officer [Member] | Equity Instruments
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 1,300		$ 1,300

Equity Awards and Warrants - Op

Equity Awards and Warrants - Options, RSUs, PSUs (Details) $ / shares in Units, shares in Thousands, $ in Thousands	Jun. 01, 2021shares	May 31, 2021USD ($)shares	Feb. 28, 2022USD ($)plan$ / sharesshares	Feb. 28, 2021USD ($)	May 31, 2021shares	Feb. 21, 2022shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of active plans | plan			1
Number of inactive plans | plan			1
Issuance of common stock upon vesting of stock based compensation awards, shares		400
Proceeds from stock option exercises | $			$ 390	$ 1,829
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares			11,200
Award vesting period			3 years
Options term			10 years
Exercise of stock option, shares			500
Proceeds from stock option exercises | $			$ 400
Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, exercise price | $ / shares			$ 2.23
Stock options grant date fair value | $ / shares			1.71
Stock options exercised, exercise price | $ / shares			1.06
Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, exercise price | $ / shares			0.58
Stock options grant date fair value | $ / shares			0.45
Stock options exercised, exercise price | $ / shares			$ 0.63
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock upon vesting of stock based compensation awards, shares			400		200
Issuance of common stock upon vesting of stock based compensation awards, value | $			$ 400
Restricted Stock Units (RSUs) [Member] | One Particular Award To Management Or Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock upon vesting of stock based compensation awards, value | $		$ 300
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock upon vesting of stock based compensation awards, shares			400
Issuance of common stock upon vesting of stock based compensation awards, value | $		$ 1,300
Stock units granted, shares			4,350
Stock units forfeited			3,900
2012 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance		50,000			50,000
Increase in number of shares authorized	6,300
Shares reallocated to be used for general purposes						15,000
Annual increase in shares authorized, as a percent of outstanding shares	1.00%
Shares available for future stock-based grants			10,300

Equity Awards and Warrants - Wa

Equity Awards and Warrants - Warrants (Details)	Mar. 25, 2022shares	Feb. 28, 2022$ / sharesshares	Feb. 16, 2022$ / sharesshares	Feb. 14, 2022$ / sharesshares	Jan. 24, 2022item	Feb. 28, 2022USD ($)$ / sharesshares	Nov. 30, 2021USD ($)$ / shares	Aug. 31, 2021USD ($)$ / shares	Feb. 28, 2021USD ($)	Nov. 30, 2020USD ($)$ / shares	Aug. 31, 2020USD ($)	Feb. 28, 2022USD ($)$ / sharesshares	Feb. 28, 2021USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercises, value | $							$ 533,000	$ 503,000	$ 3,439,000	$ 1,739,000	$ 12,690,000
Finance charges related to warrant issuance for surety bond backstop agreement | $						$ 6,585,000
Proceeds from warrant exercises | $												$ 1,036,000	$ 18,647,000
Proceeds from warrant transactions, net of offering costs | $												$ 5,390,000	$ 15,371,000
Warrant covering common stock shares purchased, percentage												12.00%
Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued during the period new issues shares	908,418
Period for payment of severance compensation					60 days
Compensation policy period					12 months
Number of monthly installments | item					6
Severance compensation, payment period from date of termination of employment					180 days
Private Equity Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercises, shares												23,500,000
Stock based compensation | $						$ 14,000
Common stock warrants to purchase shares		7,300,000				7,300,000						7,300,000
Term of warrants		5 years				5 years						5 years
Proceeds from warrant exercises | $												$ 22,400,000
Stock price, in dollars per share | $ / shares								$ 1		$ 1.50
Number of common shares in a fixed combination issue of shares		1				1						1
Number Of Warrants In Fixed Combination Issue Of Securities		0.25				0.25						0.25
Stock issued via offering, tender or placement, value | $						$ 3,552,000	27,307,000	$ 2,872,000		$ 1,000,000
Private Equity Offering | Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares			$ 1.04
Shares issued during the period new issues shares			15,000
Common stock warrants to purchase shares			25,000
Private Equity Offering | Placement Agent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		$ 0.40				$ 0.40						$ 0.40
Warrant exercises, shares												11,400,000
Shares issued during the period new issues shares												34,900,000
Common stock warrants to purchase shares		1,600,000				1,600,000						1,600,000
Term of warrants		7 years				7 years						7 years
Non-cash inducement interest expense | $												$ 1,700,000
Cash inducement interest expense | $												$ 200,000
Accredited Investors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercises, shares		1,200,000
Shares issued during the period new issues shares		2,800,000				6,300,000
Common stock warrants to purchase shares		600,000				600,000						600,000
Non-cash inducement interest expense | $						$ 1,000,000
Private Warrant Exchange [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued during the period new issues shares						7,900,000
Non-cash inducement interest expense | $												$ 5,200,000
Stock issued via offering, tender or placement, value | $							$ 4,615,000	$ 775,000	$ 3,467,000	$ 4,596,000	$ 7,804,000	$ 5,400,000
Private Warrant Exchange, Non-Inducement Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued during the period new issues shares												3,500,000
Allotment to placement agent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		$ 1				$ 1						$ 1
Term of warrants		10 years				10 years						10 years
Warrant covering common stock shares purchased, percentage												12.00%
Placement agent fees and expenses | $												$ 50,000
Stock Subscription Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		$ 1				$ 1						$ 1
Shares issued during the period new issues shares												11,400,000
Common stock warrants to purchase shares		5,000,000				5,000,000						5,000,000
Term of warrants		5 years				5 years						5 years
Number of common shares in a fixed combination issue of shares		1				1						1
Number Of Warrants In Fixed Combination Issue Of Securities		0.3				0.3						0.3
Proceeds from Issuance of Common Stock | $												$ 11,400,000
Stock issued via offering, tender or placement, value | $												10,000,000
Surety Bond Backstop Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares				$ 0.30
Stock based compensation | $						$ 6,600,000						$ 6,600,000
Common stock warrants to purchase shares		15,000,000				15,000,000						15,000,000
Term of warrants				5 years
Interest rate				10.00%
Period of Indemnification, Payment by Indemnitors				90 days
Indemnification Fee Payment Ratio				1.50%
Initial Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock warrants to purchase shares				15,000,000
Make-Whole Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock warrants to purchase shares				15,000,000
Term of warrants				5 years
Threshold period for exercise of second warrants				2 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		$ 1				$ 1						$ 1
Maximum | Private Equity Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		1.80				1.80						1.80
Stock price, in dollars per share | $ / shares		1				1	$ 1.80					1
Maximum | Accredited Investors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		1				1						1
Maximum | Private Warrant Exchange [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		1				1						1
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		0.45				0.45						0.45
Minimum | Private Equity Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		0.40				0.40						0.40
Stock price, in dollars per share | $ / shares		0.40				0.40	$ 1					0.40
Minimum | Accredited Investors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		0.40				0.40						0.40
Minimum | Private Warrant Exchange [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share | $ / shares		$ 0.40				$ 0.40						$ 0.40

Loss Per Common Share - Securit

Loss Per Common Share - Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Stock options, warrants & unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	98,309	68,857	98,309	68,857
Convertible Debt Securities
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,000	12,000	12,000	12,000
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	32,197	32,197	32,197	32,159

Income Taxes - Income Taxes (De

Income Taxes - Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended	21 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	May 31, 2021	Feb. 28, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0	$ 0	$ 0
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income tax provision at statutory rate			21.00%		21.00%
Effective income tax rate						0.00%

Commitments and Contingencies_2

Commitments and Contingencies (Details)	May 11, 2021item	Apr. 15, 2021item	Jan. 31, 2022USD ($)	Dec. 31, 2019USD ($)	Feb. 28, 2022USD ($)Dagreement	Dec. 31, 2021USD ($)	May 31, 2021USD ($)
Contractual Obligation, Fiscal Year Maturity [Abstract]
2022 (3 months remaining)					$ 2,418,000
Number of license agreements | agreement					2
Accrued license fee					$ 400,000
Prepaid royalties							$ 100,000
Research, Development And Manufacturing Agreements With Samsung [Member]
Loss Contingencies [Line Items]
Forecast period					3 years
Amount of material breach of' Master Services and Project Specific Agreements						$ 13,500,000
Additional Contractual Obligation			$ 22,800,000
Period for curing breach of contract			45 days
Termination notice period			45 days
Contractual Obligation					$ 232,789,000
Contractual Obligation, Fiscal Year Maturity [Abstract]
2023					32,221,000
2024					121,750,000
2025					76,400,000
Total					232,789,000
Termination of one trail | Maximum
Contractual Obligation, Fiscal Year Maturity [Abstract]
Potential penalties					200,000
Termination of all trails | Maximum
Contractual Obligation, Fiscal Year Maturity [Abstract]
Potential penalties					600,000
Termination of all trails | Minimum
Contractual Obligation, Fiscal Year Maturity [Abstract]
Potential penalties					$ 20,000
License Agreements With Vyera Pharmaceuticals, LLC
Contractual Obligation, Fiscal Year Maturity [Abstract]
Amount payable upon achievement of sales and regulatory milestone				$ 87,000,000
Percentage of royalty payable by the counter party				50.00%
Term of arrangement				10 years
Term of arrangement, after first commercial sale				2 years
Number of days of prior written notice | D					180
Supply And Distribution Agreement with Chiral Pharma Corporation [Member] | Covid 19 [Member]
Contractual Obligation, Fiscal Year Maturity [Abstract]
Right to distribute and sell number of drugs | item		200,000
Supply And Distribution Agreement With Macleods Pharmaceuticals Ltd. [Member] | Covid 19 [Member]
Contractual Obligation, Fiscal Year Maturity [Abstract]
Right to distribute and sell number of drugs | item	200,000
Progenics Purchase Agreement [Member]
Contractual Obligation, Fiscal Year Maturity [Abstract]
Amount of milestone payments payable					$ 5,000,000
Amount payable upon filing BLA with FDA					500,000
Amount payable upon FDA approval					500,000
Annual maintenance fees					$ 150,000
Progenics Purchase Agreement [Member] | Royalty Payable in Initial 10 Years [Member]
Contractual Obligation, Fiscal Year Maturity [Abstract]
Percentage of royalty payable					5.00%
Progenics Purchase Agreement [Member] | Royalty Payable in Longer Than10 Years [Member]
Contractual Obligation, Fiscal Year Maturity [Abstract]
Percentage of royalty payable					3.50%
Accounts Payable | Research, Development And Manufacturing Agreements With Samsung [Member]
Loss Contingencies [Line Items]
Contractual Obligation					$ 38,100,000
Contractual Obligation, Fiscal Year Maturity [Abstract]
Total					$ 38,100,000

Commitments and Contingencies -

Commitments and Contingencies - Litigation (Details) shares in Millions, $ in Millions	Jun. 04, 2021lawsuit	Nov. 30, 2020USD ($)shares
Delaware Shareholder Derivative Lawsuit [Member]
Loss Contingencies [Line Items]
Consolidated number of lawsuits | lawsuit	3
Pestell Employment Dispute [Member]
Loss Contingencies [Line Items]
Damages sought		$ 3.2
Stock units granted, shares | shares		8.3
Amount of additional damages sought		$ 31.3

Related Party Transactions (Det

Related Party Transactions (Details) - Jordan G. Naydenov shares in Millions, $ in Millions	Sep. 23, 2021USD ($)shares
Private Warrant Exchange [Member]
Related Party Transaction [Line Items]
Warrants to purchase common shares, shares	1.3
Proceeds from issuance of common shares | $	$ 0.7
Private Warrant Exchange, Inducement Shares [Member]
Related Party Transaction [Line Items]
Warrants to purchase common shares, shares	0.6
Private Warrant Exchange, Non-Inducement Shares [Member]
Related Party Transaction [Line Items]
Warrants to purchase common shares, shares	0.6

Subsequent Events (Detail)

Subsequent Events (Detail) $ / shares in Units, $ in Millions	Mar. 25, 2022individualshares	Mar. 18, 2022USD ($)$ / sharesshares	Feb. 24, 2022shares	Apr. 30, 2022shares	Feb. 28, 2022$ / sharesshares	Feb. 28, 2022USD ($)$ / sharesshares
Stock Options
Subsequent Event [Line Items]
Stock option granted, Shares						11,200,000
Award vesting period						3 years
Options term						10 years
Maximum
Subsequent Event [Line Items]
Exercise price of warrants, per share | $ / shares					$ 1	$ 1
Minimum
Subsequent Event [Line Items]
Exercise price of warrants, per share | $ / shares					$ 0.45	0.45
Private Warrant Exchange [Member]
Subsequent Event [Line Items]
Stock issued for private offering , Shares					7,900,000
Private Warrant Exchange [Member] | Maximum
Subsequent Event [Line Items]
Exercise price of warrants, per share | $ / shares					$ 1	1
Private Warrant Exchange [Member] | Minimum
Subsequent Event [Line Items]
Exercise price of warrants, per share | $ / shares					$ 0.40	$ 0.40
Private Warrant Exchange, Non-Inducement Shares [Member]
Subsequent Event [Line Items]
Stock issued for private offering , Shares						3,500,000
Private Equity Offering
Subsequent Event [Line Items]
Warrants to purchase common shares, shares					7,300,000	7,300,000
Term of warrants					5 years	5 years
Number of common shares in a fixed combination issue of shares					1	1
Private Equity Offering | Maximum
Subsequent Event [Line Items]
Exercise price of warrants, per share | $ / shares					$ 1.80	$ 1.80
Private Equity Offering | Minimum
Subsequent Event [Line Items]
Exercise price of warrants, per share | $ / shares					$ 0.40	$ 0.40
Stock Subscription Agreements [Member]
Subsequent Event [Line Items]
Warrants to purchase common shares, shares					5,000,000	5,000,000
Exercise price of warrants, per share | $ / shares					$ 1	$ 1
Stock issued for private offering , Shares						11,400,000
Term of warrants					5 years	5 years
Number of common shares in a fixed combination issue of shares					1	1
Proceeds from issuance of common stock | $						$ 11.4
Former Chief Executive Officer [Member]
Subsequent Event [Line Items]
Stock issued for private offering , Shares	908,418
Member of Company Scientific Advisory Board [Member] | Stock Options
Subsequent Event [Line Items]
Stock option granted, Shares			645,000
Subsequent Event | Private Warrant Exchange [Member]
Subsequent Event [Line Items]
Warrants to purchase common shares, shares		1,250,000
Exercise price of warrants, per share | $ / shares		$ 0.40
Stock issued for private offering , Shares		2,500,000
Term of warrants		5 years
Combined purchase price per fixed combination of a share | $ / shares		$ 0.40
Number of common shares in a fixed combination issue of shares		1
Number of shares per warrant		0.5
Proceeds from issuance of common stock | $		$ 1
Number of shares for which purchase price is reduced		1,100,000
Number of warrants for which purchase price is reduced		400,000
Subsequent Event | Private Equity Offering
Subsequent Event [Line Items]
Number of shares per warrant				0.75
Common stock per unit				1
Subsequent Event | Private Equity Offering | Maximum
Subsequent Event [Line Items]
Stock issued for private offering , Shares				61,300,000
Subsequent Event | Member of Company Scientific Advisory Board [Member]
Subsequent Event [Line Items]
Number of new member appointed to scientific advisory board | individual	4
Subsequent Event | Member of Company Scientific Advisory Board [Member] | Stock Options
Subsequent Event [Line Items]
Stock option granted, Shares	50,000
Award vesting period	3 years
Options term	10 years